{"id":"ramipril","rwe":[{"pmid":"41898697","year":"2026","title":"Steroid-Resistant Focal Segmental Glomerulosclerosis with Alport-like Glomerular Basement Membrane Lesions Due to a MYO1E Mutation: A Pediatric Case Report.","finding":"","journal":"International journal of molecular sciences","studyType":"Clinical Study"},{"pmid":"41844720","year":"2026","title":"Sexual function among controlled and uncontrolled hypertensive females receiving beta-blockers or ACEI/ARB and thiazides: a prospective randomized controlled study.","finding":"","journal":"Scientific reports","studyType":"Clinical Study"},{"pmid":"41810798","year":"2026","title":"Systemic medications associate with surgically treated cataract among adults over 50 years in Finland.","finding":"","journal":"Acta ophthalmologica","studyType":"Clinical Study"},{"pmid":"41779342","year":"2026","title":"Challenges and Perspectives in Optimising the Treatment of Arterial Hypertension: Role of the Ramipril-Amlodipine-Hydrochlorothiazide Single-Pill Combination.","finding":"","journal":"High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension","studyType":"Clinical Study"},{"pmid":"41774060","year":"2026","title":"Cardioprotective effects of prophylactic ACE inhibitors in anthracycline-induced cardiotoxicity: a systematic review and meta-analysis of randomized trials.","finding":"","journal":"Journal of cardiovascular pharmacology","studyType":"Clinical Study"}],"_fda":{"id":"cada6f46-f67d-41d9-8dbe-53740c3dac62","set_id":"01da05d8-e72e-4208-bf92-a5cd929f15ab","openfda":{"nui":["N0000175562","N0000000181"],"upc":["0363187073305"],"unii":["L35JN3I7SJ"],"route":["ORAL"],"rxcui":["198189","261962"],"spl_id":["cada6f46-f67d-41d9-8dbe-53740c3dac62"],"brand_name":["Ramipril"],"spl_set_id":["01da05d8-e72e-4208-bf92-a5cd929f15ab"],"package_ndc":["63187-073-30","63187-073-60","63187-073-90","63187-277-30","63187-277-60","63187-277-90"],"product_ndc":["63187-073","63187-277"],"generic_name":["RAMIPRIL"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["RAMIPRIL"],"pharm_class_epc":["Angiotensin Converting Enzyme Inhibitor [EPC]"],"pharm_class_moa":["Angiotensin-converting Enzyme Inhibitors [MoA]"],"manufacturer_name":["Proficient Rx LP"],"application_number":["ANDA077626"],"original_packager_product_ndc":["68180-590","68180-591"]},"version":"6","pregnancy":["8.1 Pregnancy Pregnancy Category D Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue ramipril as soon as possible. These adverse outcomes are usually associated with use of these drugs in the second and third trimester of pregnancy. Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. Appropriate management of maternal hypertension during pregnancy is important to optimize outcomes for both mother and fetus. In the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus. Perform serial ultrasound examinations to assess the intra-amniotic environment. If oligohydramnios is observed, discontinue ramipril unless it is considered life-saving for the mother. Fetal testing may be appropriate, based on the week of pregnancy. Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury. Closely observe infants with histories of in utero exposure to ramipril for hypotension, oliguria, and hyperkalemia [see USE IN SPECIFIC POPULATIONS ( 8.4 ) ].","17.4 Pregnancy Female patients of childbearing age should be told about the consequences of exposure to ramipril during pregnancy. Discuss treatment options with women planning to become pregnant. Patients should be asked to report pregnancies to their physicians as soon as possible."],"overdosage":["10. OVERDOSAGE Single oral doses of ramipril in rats and mice of 10 g/kg to 11 g/kg resulted in significant lethality. In dogs, oral doses as high as 1 g/kg induced only mild gastrointestinal distress. Limited data on human overdosage are available. The most likely clinical manifestations would be symptoms attributable to hypotension. Laboratory determinations of serum levels of ramipril and its metabolites are not widely available, and such determinations have, in any event, no established role in the management of ramipril overdose. No data are available to suggest physiological maneuvers (e.g., maneuvers to change the pH of the urine) that might accelerate elimination of ramipril and its metabolites. Similarly, it is not known which, if any, of these substances can be effectively removed from the body by hemodialysis. Angiotensin II could presumably serve as a specific antagonist-antidote in the setting of ramipril overdose, but angiotensin II is essentially unavailable outside of scattered research facilities. Because the hypotensive effect of ramipril is achieved through vasodilation and effective hypovolemia, it is reasonable to treat ramipril overdose by infusion of normal saline solution."],"description":["11. DESCRIPTION Ramipril is a 2-aza-bicyclo [3.3.0]-octane-3-carboxylic acid derivative. It is a white, crystalline substance soluble in polar organic solvents and buffered aqueous solutions. Ramipril melts between 105°-112°C. The CAS Registry Number is 87333-19-5. Ramipril's chemical name is (2S,3aS,6aS)-1[(S)-N-[(S)-1-Carboxy-3-phenylpropyl] alanyl] octahydrocyclopenta [ b ]pyrrole-2-carboxylic acid, 1-ethyl ester. Ramipril capsules USP are supplied as hard gelatin capsules for oral administration containing 1.25 mg, 2.5 mg, 5 mg, and 10 mg of ramipril. The inactive ingredients present are gelatin, meglumine, pregelatinized starch, and titanium dioxide. The 1.25 mg capsule shell contains yellow iron oxide, the 2.5 mg capsule contains D&C yellow #10 and FD&C red #40, the 5 mg capsule shell contains FD&C blue #1 and FD&C red #40, and the 10 mg capsule shell contains FD&C blue #1. The structural formula for ramipril is: Its empirical formula is C 23 H 32 N 2 O 5 and its molecular weight is 416.5. Ramiprilat, the diacid metabolite of ramipril, is a non-sulfhydryl ACE inhibitor. Ramipril is converted to ramiprilat by hepatic cleavage of the ester group. structural formula for ramipril"],"how_supplied":["16. HOW SUPPLIED/STORAGE AND HANDLING Ramipril Capsules, USP are available in 5 mg and 10 mg hard gelatin capsules. Descriptions of Ramipril Capsules USP are summarized below. Ramipril Capsules USP, 5 mg are: Size \"4\" capsules with red cap, imprinted with 'LUPIN' in black ink and red body imprinted with 'RAMIPRIL 5 mg' in black ink, containing white to off-white powder. NDC 63187-073-30 bottles of 30 NDC 63187-073-60 bottles of 60 NDC 63187-073-90 bottles of 90 Ramipril Capsules USP, 10 mg are: Size \"4\" capsules with light blue cap, imprinted with 'LUPIN' in black ink and light blue body imprinted with 'RAMIPRIL 10 mg' in black ink, containing white to off-white powder. NDC 63187-277-30 bottles of 30 NDC 63187-277-60 bottles of 60 NDC 63187-277-90 bottles of 90 Dispense in light-resistant, tight container with child-resistant closure. Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]."],"boxed_warning":["WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning • When pregnancy is detected, discontinue ramipril as soon as possible ( 5.6 ). • Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus ( 5.6 ). WARNING: FETAL TOXICITY • When pregnancy is detected, discontinue ramipril as soon as possible ( 5.6 ). • Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus ( 5.6 )."],"geriatric_use":["8.5 Geriatric Use Of the total number of patients who received ramipril in U.S. clinical studies of ramipril, 11.0% were ≥65 years of age while 0.2% were ≥75 years of age. No overall differences in effectiveness or safety were observed between these patients and younger patients, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but a greater sensitivity of some older individuals cannot be ruled out. One pharmacokinetic study conducted in hospitalized elderly patients indicated that peak ramiprilat levels and area under the plasma concentration-time curve (AUC) for ramiprilat are higher in older patients."],"pediatric_use":["8.4 Pediatric Use Neonates with a history of in utero exposure to ramipril If oliguria or hypotension occurs, direct attention toward support of blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing hypotension and/or substituting for disordered renal function. Ramipril, which crosses the placenta, can theoretically be removed from the neonatal circulation by these means, but limited experience has not shown that such removal is central to the treatment of these infants. Safety and effectiveness in pediatric patients have not been established. Irreversible kidney damage has been observed in very young rats given a single dose of ramipril."],"effective_time":"20220701","nursing_mothers":["8.3 Nursing Mothers Ingestion of a single 10 mg oral dose of ramipril resulted in undetectable amounts of ramipril and its metabolites in breast milk. However, because multiple doses may produce low milk concentrations that are not predictable from a single dose, do not use ramipril in nursing mothers."],"clinical_studies":["14. CLINICAL STUDIES 14.1 Hypertension Ramipril has been compared with other ACE inhibitors, beta-blockers, and thiazide diuretics as monotherapy for hypertension. It was approximately as effective as other ACE inhibitors and as atenolol. Administration of ramipril to patients with mild to moderate hypertension results in a reduction of both supine and standing blood pressure to about the same extent with no compensatory tachycardia. Symptomatic postural hypotension is infrequent, although it can occur in patients who are salt- and/or volume-depleted [see WARNINGS AND PRECAUTIONS ( 5.5 ) ]. Use of ramipril in combination with thiazide diuretics gives a blood pressure lowering effect greater than that seen with either agent alone. In single-dose studies, doses of 5 mg to 20 mg of ramipril lowered blood pressure within 1 to 2 hours, with peak reductions achieved 3 to 6 hours after dosing. The antihypertensive effect of a single dose persisted for 24 hours. In longer term (4 to 12 weeks) controlled studies, once-daily doses of 2.5 mg to 10 mg were similar in their effect, lowering supine or standing systolic and diastolic blood pressures 24 hours after dosing by about 6/4 mmHg more than placebo. In comparisons of peak vs. trough effect, the trough effect represented about 50 to 60% of the peak response. In a titration study comparing divided (bid) vs. qd treatment, the divided regimen was superior, indicating that for some patients, the antihypertensive effect with once-daily dosing is not adequately maintained. In most trials, the antihypertensive effect of ramipril increased during the first several weeks of repeated measurements. The antihypertensive effect of ramipril has been shown to continue during long-term therapy for at least 2 years. Abrupt withdrawal of ramipril has not resulted in a rapid increase in blood pressure. Ramipril has been compared with other ACE inhibitors, beta-blockers, and thiazide diuretics. Ramipril was approximately as effective as other ACE inhibitors and as atenolol. In both Caucasians and Blacks, hydrochlorothiazide (25 or 50 mg) was significantly more effective than ramipril. Ramipril was less effective in blacks than in Caucasians. The effectiveness of ramipril was not influenced by age, sex, or weight. In a baseline controlled study of 10 patients with mild essential hypertension, blood pressure reduction was accompanied by a 15% increase in renal blood flow. In healthy volunteers, glomerular filtration rate was unchanged. 14.3 Heart Failure Post-Myocardial Infarction Ramipril was studied in the AIRE trial. This was a multinational (mainly European) 161-center, 2006-patient, double-blind, randomized, parallel-group study comparing ramipril to placebo in stable patients, 2 to 9 days after an acute myocardial infarction, who had shown clinical signs of congestive heart failure at any time after the myocardial infarction. Patients in severe (NYHA class IV) heart failure, patients with unstable angina, patients with heart failure of congenital or valvular etiology, and patients with contraindications to ACE inhibitors were all excluded. The majority of patients had received thrombolytic therapy at the time of the index infarction, and the average time between infarction and initiation of treatment was 5 days. Patients randomized to ramipril treatment were given an initial dose of 2.5 mg twice daily. If the initial regimen caused undue hypotension, the dose was reduced to 1.25 mg, but in either event doses were titrated upward (as tolerated) to a target regimen (achieved in 77% of patients randomized to ramipril) of 5 mg twice daily. Patients were then followed for an average of 15 months, with the range of follow-up between 6 and 46 months. The use of ramipril was associated with a 27% reduction (p=0.002) in the risk of death from any cause; about 90% of the deaths that occurred were cardiovascular, mainly sudden death. The risks of progression to severe heart failure and of congestive heart failure-related hospitalization were also reduced, by 23% (p=0.017) and 26% (p=0.011), respectively. The benefits of ramipril therapy were seen in both genders, and they were not affected by the exact timing of the initiation of therapy, but older patients may have had a greater benefit than those under 65. The benefits were seen in patients on (and not on) various concomitant medications. At the time of randomization these included aspirin (about 80% of patients), diuretics (about 60%), organic nitrates (about 55%), beta-blockers (about 20%), calcium channel blockers (about 15%), and digoxin (about 12%)."],"pharmacodynamics":["12.2 Pharmacodynamics Single doses of ramipril of 2.5 mg to 20 mg produce approximately 60% to 80% inhibition of ACE activity 4 hours after dosing with approximately 40% to 60% inhibition after 24 hours. Multiple oral doses of ramipril of 2.0 mg or more cause plasma ACE activity to fall by more than 90% 4 hours after dosing, with over 80% inhibition of ACE activity remaining 24 hours after dosing. The more prolonged effect of even small multiple doses presumably reflects saturation of ACE binding sites by ramiprilat and relatively slow release from those sites."],"pharmacokinetics":["12.3 Pharmacokinetics Absorption Following oral administration of ramipril, peak plasma concentrations (C max ) of ramipril are reached within 1 hour. The extent of absorption is at least 50% to 60%, and is not significantly influenced by the presence of food in the gastrointestinal tract, although the rate of absorption is reduced. In a trial in which subjects received ramipril capsules or the contents of identical capsules dissolved in water, dissolved in apple juice, or suspended in applesauce, serum ramiprilat levels were essentially unrelated to the use or non-use of the concomitant liquid or food. Distribution Cleavage of the ester group (primarily in the liver) converts ramipril to its active diacid metabolite, ramiprilat. Peak plasma concentrations of ramiprilat are reached 2 to 4 hours after drug intake. The serum protein binding of ramipril is about 73% and that of ramiprilat about 56%; in vitro, these percentages are independent of concentration over the range of 0.01 μg/mL to10 μg/mL. Metabolism Ramipril is almost completely metabolized to ramiprilat, which has about 6 times the ACE inhibitory activity of ramipril, and to the diketopiperazine ester, the diketopiperazine acid, and the glucuronides of ramipril and ramiprilat, all of which are inactive. Plasma concentrations of ramipril and ramiprilat increase with increased dose, but are not strictly dose-proportional. The 24-hour AUC for ramiprilat, however, is dose-proportional over the 2 .5 mg to 20 mg dose range. The absolute bioavailabilities of ramipril and ramiprilat were 28% and 44%, respectively, when 5 mg of oral ramipril was compared with the same dose of ramipril given intravenously. After once-daily dosing, steady-state plasma concentrations of ramiprilat are reached by the fourth dose. Steady-state concentrations of ramiprilat are somewhat higher than those seen after the first dose of ramipril, especially at low doses (2.5 mg), but the difference is clinically insignificant. Plasma concentrations of ramiprilat decline in a triphasic manner (initial rapid decline, apparent elimination phase, terminal elimination phase). The initial rapid decline, which represents distribution of the drug into a large peripheral compartment and subsequent binding to both plasma and tissue ACE, has a half-life of 2 to 4 hours. Because of its potent binding to ACE and slow dissociation from the enzyme, ramiprilat shows two elimination phases. The apparent elimination phase corresponds to the clearance of free ramiprilat and has a half-life of 9 to 18 hours. The terminal elimination phase has a prolonged half-life (>50 hours) and probably represents the binding/dissociation kinetics of the ramiprilat/ACE complex. It does not contribute to the accumulation of the drug. After multiple daily doses of ramipril 5 mg to 10 mg, the half-life of ramiprilat concentrations within the therapeutic range was 13 to 17 hours. In patients with creatinine clearance <40 mL/min/1.73 m 2 , peak levels of ramiprilat are approximately doubled, and trough levels may be as much as quintupled. In multiple-dose regimens, the total exposure to ramiprilat (AUC) in these patients is 3 to 4 times as large as it is in patients with normal renal function who receive similar doses. In patients with impaired liver function, the metabolism of ramipril to ramiprilat appears to be slowed, possibly because of diminished activity of hepatic esterases, and plasma ramipril levels in these patients are increased about 3-fold. Peak concentrations of ramiprilat in these patients, however, are not different from those seen in subjects with normal hepatic function, and the effect of a given dose on plasma ACE activity does not vary with hepatic function. Excretion After oral administration of ramipril, about 60% of the parent drug and its metabolites are eliminated in the urine, and about 40% is found in the feces. Drug recovered in the feces may represent both biliary excretion of metabolites and/or unabsorbed drug, however the proportion of a dose eliminated by the bile has not been determined. Less than 2% of the administered dose is recovered in urine as unchanged ramipril. The urinary excretion of ramipril, ramiprilat, and their metabolites is reduced in patients with impaired renal function. Compared to normal subjects, patients with creatinine clearance <40 mL/min/1.73 m 2 had higher peak and trough ramiprilat levels and slightly longer times to peak concentrations."],"adverse_reactions":["6. ADVERSE REACTIONS The most common adverse reactions in patients with hypertension included headache, dizziness, fatigue, and cough ( 6.1 ). To report SUSPECTED ADVERSE REACTIONS, contact Lupin Pharmaceuticals, Inc at 1-800-399-2561 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Hypertension Ramipril has been evaluated for safety in over 4000 patients with hypertension; of these, 1230 patients were studied in U.S. controlled trials, and 1107 were studied in foreign controlled trials. Almost 700 of these patients were treated for at least one year. The overall incidence of reported adverse events was similar in ramipril and placebo patients. The most frequent clinical side effects (possibly or probably related to study drug) reported by patients receiving ramipril in placebo-controlled trials were: headache (5.4%), dizziness (2.2%), and fatigue or asthenia (2.0%), but only the last one was more common in ramipril patients than in patients given placebo. Generally the side effects were mild and transient, and there was no relation to total dosage within the range of 1.25 mg–20 mg. Discontinuation of therapy because of a side effect was required in approximately 3% of U.S. patients treated with ramipril. The most common reasons for discontinuation were: cough (1.0%), dizziness (0.5%), and impotence (0.4%). Of observed side effects considered possibly or probably related to study drug that occurred in U.S. placebo-controlled trials in more than 1% of patients treated with ramipril, only asthenia (fatigue) was more common on ramipril than placebo (2% [n=13/651] vs. 1% [n=2/286], respectively). In placebo-controlled trials, there was also an excess of upper respiratory infection and flu syndrome i n the Ramipril group, not attributed at that time to ramipril. As these studies were carried out before the relationship of cough to ACE inhibitors was recognized, some of these events may represent ramipril-induced cough. In a later 1-year study, increased cough was seen in almost 12% of ramipril patients, with about 4% of patients requiring discontinuation of treatment. Heart Failure Post-Myocardial Infarction AIRE Study: Adverse reactions (except laboratory abnormalities) considered possibly/probably related to study drug that occurred in more than 1% of patients and more frequently on ramipril are shown below. The incidences are from the AIRE study. The follow-up time was between 6 and 46 months for this study. Table 1. Percentage of Patients with Adverse Events Possibly/ Probably Related to Study Drug—Placebo-Controlled (AIRE) Mortality Study Adverse Event Placebo (N=982) Ramipril (N=1004) Hypotension 5% 11% Cough increased 4% 8% Dizziness 3% 4% Angina pectoris 2% 3% Nausea 1% 2% Postural hypotension 1% 2% Syncope 1% 2% Vomiting 0.5% 2% Vertigo 0.7% 2% Abnormal kidney function 0.5% 1% Diarrhea 0.4% 1% Other Adverse Reactions Other adverse reactions reported in controlled clinical trials (in less than 1% of ramipril patients), or rarer events seen in post-marketing experience, include the following (in some, a causal relationship to drug is uncertain): Body as a whole: Anaphylactoid reactions [see WARNINGS AND PRECAUTIONS ( 5.1 ) ]. Cardiovascular: Symptomatic hypotension (reported in 0.5% of patients in U.S. trials) [see WARNINGS AND PRECAUTIONS ( 5.5 ) ] , syncope, and palpitations. Hematologic: Pancytopenia, hemolytic anemia, and thrombocytopenia. Decreases in hemoglobin or hematocrit (a low value and a decrease of 5 g/dL or 5%, respectively) were rare, occurring in 0.4% of patients receiving ramipril alone and in 1.5% of patients receiving ramipril plus a diuretic. Renal: Acute renal failure. Some hypertensive patients with no apparent pre-existing renal disease have developed minor, usually transient, increases in blood urea nitrogen and serum creatinine when taking ramipril, particularly when ramipril was given concomitantly with a diuretic [see WARNINGS AND PRECAUTIONS ( 5.3 ) ]. Angioneurotic edema: Angioneurotic edema has been reported in 0.3% of patients in U.S. clinical trials of ramipril [see WARNINGS AND PRECAUTIONS ( 5.1 ) ]. Gastrointestinal: Hepatic failure, hepatitis, jaundice, pancreatitis, abdominal pain (sometimes with enzyme changes suggesting pancreatitis), anorexia, constipation, diarrhea, dry mouth, dyspepsia, dysphagia, gastroenteritis, increased salivation, and taste disturbance. Dermatologic: Apparent hypersensitivity reactions (manifested by urticaria, pruritus, or rash, with or without fever), photosensitivity, purpura, onycholysis, pemphigus, pemphigoid, erythema multiforme, toxic epidermal necrolysis, and Stevens-Johnson syndrome. Neurologic and Psychiatric: Anxiety, amnesia, convulsions, depression, hearing loss, insomnia, nervousness, neuralgia, neuropathy, paresthesia, somnolence, tinnitus, tremor, vertigo, and vision disturbances. Miscellaneous: As with other ACE inhibitors, a symptom complex has been reported which may include a positive ANA, an elevated erythrocyte sedimentation rate, arthralgia/arthritis, myalgia, fever, vasculitis, eosinophilia, photosensitivity, rash and other dermatologic manifestations. Additionally, as with other ACE inhibitors, eosinophilic pneumonitis has been reported. Other: Arthralgia, arthritis, dyspnea, edema, epistaxis, impotence, increased sweating, malaise, myalgia, and weight gain. 6.2 Post-Marketing Experience In addition to adverse reactions reported from clinical trials, there have been rare reports of hypoglycemia reported during ramipril therapy when given to patients concomitantly taking oral hypoglycemic agents or insulin. The causal relationship is unknown. 6.3 Clinical Laboratory Test Findings Creatinine and Blood Urea Nitrogen Increases in creatinine levels occurred in 1.2% of patients receiving ramipril alone, and in 1.5% of patients receiving ramipril and a diuretic. Increases in blood urea nitrogen levels occurred in 0.5% of patients receiving ramipril alone and in 3% of patients receiving ramipril with a diuretic. None of these increases required discontinuation of treatment. Increases in these laboratory values are more likely to occur in patients with renal insufficiency or those pretreated with a diuretic and, based on experience with other ACE inhibitors, would be expected to be especially likely in patients with renal artery stenosis [see WARNINGS AND PRECAUTIONS ( 5.3 ) ]. As ramipril decreases aldosterone secretion, elevation of serum potassium can occur. Use potassium supplements and potassium sparing diuretics with caution, and monitor the patient's serum potassium frequently [see WARNINGS AND PRECAUTIONS ( 5.8 ) ] . Hemoglobin and Hematocrit Decreases in hemoglobin or hematocrit (a low value and a decrease of 5 g/dL or 5%, respectively) were rare, occurring in 0.4% of patients receiving ramipril alone and in 1.5% of patients receiving ramipril plus a diuretic. No US patients discontinued treatment because of decreases in hemoglobin or hematocrit. Other (causal relationships unknown) Clinically important changes in standard laboratory tests were rarely associated with Ramipril administration. Elevations of liver enzymes, serum bilirubin, uric acid, and blood glucose have been reported, as have cases of hyponatremia and scattered incidents of leucopenia, eosinophilia, and proteinuria. In US trials, less than 0.2% of patients discontinued treatment for laboratory abnormalities; all of these were cases of proteinuria or abnormal liver-function tests."],"contraindications":["4. CONTRAINDICATIONS Angioedema related to previous treatment with an ACE inhibitor, or a history of hereditary or idiopathic angioedema.( 4 ). Ramipril is contraindicated in patients who are hypersensitive to this product or any other ACE inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor)."],"drug_interactions":["7. DRUG INTERACTIONS • Diuretics: Possibility of excessive hypotension ( 7.1 ). • Lithium: Use with caution ( 7.3 ). • Gold: Nitritoid reactions have been reported ( 7.4 ). • NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7.5 ). 7.1 Diuretics Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either decreasing or discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. If this is not possible, reduce the starting dose [see DOSAGE AND ADMINISTRATION ( 2 ) ]. Ramipril can attenuate potassium loss caused by thiazide diuretics. Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, monitor the patient's serum potassium frequently. 7.2 Other Antihypertensive Agents Limited experience in controlled and uncontrolled trials combining ramipril with a calcium channel blocker, a loop diuretic, or triple therapy (beta-blocker, vasodilator, and a diuretic) indicate no unusual drug-drug interactions. Other ACE inhibitors have had less than additive effects with beta adrenergic blockers, presumably because both drug classes lower blood pressure by inhibiting parts of the renin-angiotensin-aldosterone system. The combination of ramipril and propranolol showed no adverse effects on dynamic parameters (blood pressure and heart rate). In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see Dual Blockade of the Renin-Angiotensin-Aldosterone System ( 5.7 ) ]. 7.3 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased. 7.4 Gold Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy including ramipril. 7.5 Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including ramipril, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving ramipril and NSAID therapy. The antihypertensive effect of ACE inhibitors, including ramipril, may be attenuated by NSAIDs. 7.6 Other Neither ramipril nor its metabolites have been found to interact with food, digoxin, antacid, furosemide, cimetidine, indomethacin, and simvastatin. The co-administration of ramipril and warfarin did not adversely affect the anticoagulation effects of the latter drug. Additionally, co-administration of ramipril with phenprocoumon did not affect minimum phenprocoumon levels or interfere with the patients' state of anticoagulation."],"mechanism_of_action":["12.1 Mechanism of Action Ramipril and ramiprilat inhibit ACE in human subjects and animals. Angiotensin converting enzyme is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. Inhibition of ACE results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and to decreased aldosterone secretion. The latter decrease may result in a small increase of serum potassium. In hypertensive patients with normal renal function treated with ramipril alone for up to 56 weeks, approximately 4% of patients during the trial had an abnormally high serum potassium and an increase from baseline greater than 0.75 mEq/L, and none of the patients had an abnormally low potassium and a decrease from baseline greater than 0.75 mEq/L. In the same study, approximately 2% of patients treated with ramipril and hydrochlorothiazide for up to 56 weeks had abnormally high potassium values and an increase from baseline of 0.75 mEq/L or greater; and approximately 2% had abnormally low values and decreases from baseline of 0.75 mEq/L or greater [see WARNINGS AND PRECAUTIONS ( 5.8 ) ]. Removal of angiotensin II negative feedback on renin secretion leads to increased plasma renin activity. The effect of ramipril on hypertension appears to result at least in part from inhibition of both tissue and circulating ACE activity, thereby reducing angiotensin II formation in tissue and plasma. Angiotensin converting enzyme is identical to kininase, an enzyme that degrades bradykinin. Whether increased levels of bradykinin, a potent vasopressor peptide, play a role in the therapeutic effects of ramipril remains to be elucidated. While the mechanism through which ramipril lowers blood pressure is believed to be primarily suppression of the reninangiotensin-aldosterone system, ramipril has an antihypertensive effect even in patients with low-renin hypertension. Although ramipril was antihypertensive in all races studied, Black hypertensive patients (usually a low-renin hypertensive population) had a blood pressure lowering response to monotherapy, albeit a smaller average response, than non-Black patients."],"recent_major_changes":["Boxed Warning: Fetal Toxicity 04/2012 Warnings and Precautions: Fetal Toxicity ( 5.6 ) 04/2012"],"clinical_pharmacology":["12. CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Ramipril and ramiprilat inhibit ACE in human subjects and animals. Angiotensin converting enzyme is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. Inhibition of ACE results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and to decreased aldosterone secretion. The latter decrease may result in a small increase of serum potassium. In hypertensive patients with normal renal function treated with ramipril alone for up to 56 weeks, approximately 4% of patients during the trial had an abnormally high serum potassium and an increase from baseline greater than 0.75 mEq/L, and none of the patients had an abnormally low potassium and a decrease from baseline greater than 0.75 mEq/L. In the same study, approximately 2% of patients treated with ramipril and hydrochlorothiazide for up to 56 weeks had abnormally high potassium values and an increase from baseline of 0.75 mEq/L or greater; and approximately 2% had abnormally low values and decreases from baseline of 0.75 mEq/L or greater [see WARNINGS AND PRECAUTIONS ( 5.8 ) ]. Removal of angiotensin II negative feedback on renin secretion leads to increased plasma renin activity. The effect of ramipril on hypertension appears to result at least in part from inhibition of both tissue and circulating ACE activity, thereby reducing angiotensin II formation in tissue and plasma. Angiotensin converting enzyme is identical to kininase, an enzyme that degrades bradykinin. Whether increased levels of bradykinin, a potent vasopressor peptide, play a role in the therapeutic effects of ramipril remains to be elucidated. While the mechanism through which ramipril lowers blood pressure is believed to be primarily suppression of the reninangiotensin-aldosterone system, ramipril has an antihypertensive effect even in patients with low-renin hypertension. Although ramipril was antihypertensive in all races studied, Black hypertensive patients (usually a low-renin hypertensive population) had a blood pressure lowering response to monotherapy, albeit a smaller average response, than non-Black patients. 12.2 Pharmacodynamics Single doses of ramipril of 2.5 mg to 20 mg produce approximately 60% to 80% inhibition of ACE activity 4 hours after dosing with approximately 40% to 60% inhibition after 24 hours. Multiple oral doses of ramipril of 2.0 mg or more cause plasma ACE activity to fall by more than 90% 4 hours after dosing, with over 80% inhibition of ACE activity remaining 24 hours after dosing. The more prolonged effect of even small multiple doses presumably reflects saturation of ACE binding sites by ramiprilat and relatively slow release from those sites. 12.3 Pharmacokinetics Absorption Following oral administration of ramipril, peak plasma concentrations (C max ) of ramipril are reached within 1 hour. The extent of absorption is at least 50% to 60%, and is not significantly influenced by the presence of food in the gastrointestinal tract, although the rate of absorption is reduced. In a trial in which subjects received ramipril capsules or the contents of identical capsules dissolved in water, dissolved in apple juice, or suspended in applesauce, serum ramiprilat levels were essentially unrelated to the use or non-use of the concomitant liquid or food. Distribution Cleavage of the ester group (primarily in the liver) converts ramipril to its active diacid metabolite, ramiprilat. Peak plasma concentrations of ramiprilat are reached 2 to 4 hours after drug intake. The serum protein binding of ramipril is about 73% and that of ramiprilat about 56%; in vitro, these percentages are independent of concentration over the range of 0.01 μg/mL to10 μg/mL. Metabolism Ramipril is almost completely metabolized to ramiprilat, which has about 6 times the ACE inhibitory activity of ramipril, and to the diketopiperazine ester, the diketopiperazine acid, and the glucuronides of ramipril and ramiprilat, all of which are inactive. Plasma concentrations of ramipril and ramiprilat increase with increased dose, but are not strictly dose-proportional. The 24-hour AUC for ramiprilat, however, is dose-proportional over the 2 .5 mg to 20 mg dose range. The absolute bioavailabilities of ramipril and ramiprilat were 28% and 44%, respectively, when 5 mg of oral ramipril was compared with the same dose of ramipril given intravenously. After once-daily dosing, steady-state plasma concentrations of ramiprilat are reached by the fourth dose. Steady-state concentrations of ramiprilat are somewhat higher than those seen after the first dose of ramipril, especially at low doses (2.5 mg), but the difference is clinically insignificant. Plasma concentrations of ramiprilat decline in a triphasic manner (initial rapid decline, apparent elimination phase, terminal elimination phase). The initial rapid decline, which represents distribution of the drug into a large peripheral compartment and subsequent binding to both plasma and tissue ACE, has a half-life of 2 to 4 hours. Because of its potent binding to ACE and slow dissociation from the enzyme, ramiprilat shows two elimination phases. The apparent elimination phase corresponds to the clearance of free ramiprilat and has a half-life of 9 to 18 hours. The terminal elimination phase has a prolonged half-life (>50 hours) and probably represents the binding/dissociation kinetics of the ramiprilat/ACE complex. It does not contribute to the accumulation of the drug. After multiple daily doses of ramipril 5 mg to 10 mg, the half-life of ramiprilat concentrations within the therapeutic range was 13 to 17 hours. In patients with creatinine clearance <40 mL/min/1.73 m 2 , peak levels of ramiprilat are approximately doubled, and trough levels may be as much as quintupled. In multiple-dose regimens, the total exposure to ramiprilat (AUC) in these patients is 3 to 4 times as large as it is in patients with normal renal function who receive similar doses. In patients with impaired liver function, the metabolism of ramipril to ramiprilat appears to be slowed, possibly because of diminished activity of hepatic esterases, and plasma ramipril levels in these patients are increased about 3-fold. Peak concentrations of ramiprilat in these patients, however, are not different from those seen in subjects with normal hepatic function, and the effect of a given dose on plasma ACE activity does not vary with hepatic function. Excretion After oral administration of ramipril, about 60% of the parent drug and its metabolites are eliminated in the urine, and about 40% is found in the feces. Drug recovered in the feces may represent both biliary excretion of metabolites and/or unabsorbed drug, however the proportion of a dose eliminated by the bile has not been determined. Less than 2% of the administered dose is recovered in urine as unchanged ramipril. The urinary excretion of ramipril, ramiprilat, and their metabolites is reduced in patients with impaired renal function. Compared to normal subjects, patients with creatinine clearance <40 mL/min/1.73 m 2 had higher peak and trough ramiprilat levels and slightly longer times to peak concentrations."],"indications_and_usage":["1. INDICATIONS AND USAGE • Ramipril capsules USP are indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics. ( 1.1 ). • Ramipril capsules USP are indicated in stable patients who have demonstrated clinical signs of congestive heart failure post-myocardial infarction ( 1.3 ). 1.1 Hypertension Ramipril capsules USP are indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics. 1.3 Heart Failure Post-Myocardial Infarction Ramipril capsules USP are indicated in stable patients who have demonstrated clinical signs of congestive heart failure within the first few days after sustaining acute myocardial infarction. Administration of ramipril to such patients has been shown to decrease the risk of death (principally cardiovascular death) and to decrease the risks of failure-related hospitalization and progression to severe/resistant heart failure [see CLINICAL STUDIES ( 14.3 ) ]."],"warnings_and_cautions":["5. WARNINGS AND PRECAUTIONS ACE inhibitor use has been associated with the following: • Angioedema, with increased risk in patients with a prior history ( 5.1 ) • Hypotension and hyperkalemia ( 5.5 , 5.8 ) • Renal impairment: monitor renal function during therapy ( 5.3 ) • Increased risk of renal impairment when combined with another blocker of the renin-angiotensin-aldosterone system ( 5.7 ) • Rare cholestatic jaundice and hepatic failure ( 5.2 ) • Rare neutropenia and agranulocytosis ( 5.4 ) 5.1 Anaphylactoid and Possibly Related Reactions Presumably because drugs that act directly on the renin-angiotensin-aldosterone system (e.g., ACE inhibitors) affect the metabolism of eicosanoids and polypeptides, including endogenous bradykinin, patients receiving these drugs (including ramipril) may be subject to a variety of adverse reactions, some of them serious. Angioedema Head and Neck Angioedema: Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased risk of angioedema while receiving an ACE inhibitor. Angioedema of the face, extremities, lips, tongue, glottis, and larynx has been reported in patients treated with ACE inhibitors. Angioedema associated with laryngeal edema can be fatal. If laryngeal stridor or angioedema of the face, tongue, or glottis occurs, discontinue treatment with ramipril and institute appropriate therapy immediately. Where there is involvement of the tongue, glottis, or larynx likely to cause airway obstruction, administer appropriate therapy (e.g., subcutaneous epinephrine solution 1:1000 [0.3 mL to 0.5 mL]) promptly [see ADVERSE REACTIONS ( 6 ) ]. In considering the use of ramipril, note that in controlled clinical trials ACE inhibitors cause a higher rate of angioedema in Black patients than in non-Black patients. In a large U.S. post-marketing study, angioedema (defined as reports of angio, face, larynx, tongue, or throat edema) was reported in 3/1523 (0.20%) Black patients and in 8/8680 (0.09%) non-Black patients. These rates were not different statistically. Intestinal Angioedema: Intestinal angioedema has been reported in patients treated with ACE inhibitors. These patients presented with abdominal pain (with or without nausea or vomiting); in some cases there was no prior history of facial angioedema and C-1 esterase levels were normal. The angioedema was diagnosed by procedures including abdominal CT scan or ultrasound, or at surgery, and symptoms resolved after stopping the ACE inhibitor. Include intestinal angioedema in the differential diagnosis of patients on ACE inhibitors presenting with abdominal pain. Anaphylactoid Reactions During Desensitization Two patients undergoing desensitizing treatment with hymenoptera venom while receiving ACE inhibitors sustained life-threatening anaphylactoid reactions. In the same patients, these reactions were avoided when ACE inhibitors were temporarily withheld, but they reappeared upon inadvertent rechallenge. Anaphylactoid Reactions During Membrane Exposure Anaphylactoid reactions have been reported in patients dialyzed with high-flux membranes and treated concomitantly with an ACE inhibitor. Anaphylactoid reactions have also been reported in patients undergoing low-density lipoprotein apheresis with dextran sulfate absorption. 5.2 Hepatic Failure and Impaired Liver Function Rarely, ACE inhibitors, including ramipril, have been associated with a syndrome that starts with cholestatic jaundice and progresses to fulminant hepatic necrosis and sometimes death. The mechanism of this syndrome is not understood. Discontinue ramipril if patient develops jaundice or marked elevations of hepatic enzymes. As ramipril is primarily metabolized by hepatic esterases to its active moiety, ramiprilat, patients with impaired liver function could develop markedly elevated plasma levels of ramipril. No formal pharmacokinetic studies have been carried out in hypertensive patients with impaired liver function. 5.3 Renal Impairment As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals. In patients with severe congestive heart failure whose renal function may depend on the activity of the renin-angiotensin-aldosterone system, treatment with ACE inhibitors, including ramipril, may be associated with oliguria or progressive azotemia and rarely with acute renal failure or death. In hypertensive patients with unilateral or bilateral renal artery stenosis, increases in blood urea nitrogen and serum creatinine may occur. Experience with another ACE inhibitor suggests that these increases would be reversible upon discontinuation of ramipril and/or diuretic therapy. In such patients, monitor renal function during the first few weeks of therapy. Some hypertensive patients with no apparent pre-existing renal vascular disease have developed increases in blood urea nitrogen and serum creatinine, usually minor and transient, especially when ramipril has been given concomitantly with a diuretic. This is more likely to occur in patients with pre-existing renal impairment. Dosage reduction of ramipril and/or discontinuation of the diuretic may be required. 5.4 Neutropenia and Agranulocytosis In rare instances, treatment with ACE inhibitors may be associated with mild reductions in red blood cell count and hemoglobin content, blood cell or platelet counts. In isolated cases, agranulocytosis, pancytopenia, and bone marrow depression may occur. Hematological reactions to ACE inhibitors are more likely to occur in patients with collagen-vascular disease (e.g., systemic lupus erythematosus, scleroderma) and renal impairment. Consider monitoring white blood cell counts in patients with collagen-vascular disease, especially if the disease is associated with impaired renal function. 5.5 Hypotension General Considerations Ramipril can cause symptomatic hypotension, after either the initial dose or a later dose when the dosage has been increased. Like other ACE inhibitors, ramipril, has been only rarely associated with hypotension in uncomplicated hypertensive patients. Symptomatic hypotension is most likely to occur in patients who have been volume- and/or salt-depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. Correct volume- and salt-depletion before initiating therapy with Ramipril. If excessive hypotension occurs, place the patient in a supine position and, if necessary, treat with intravenous infusion of physiological saline. Ramipril treatment usually can be continued following restoration of blood pressure and volume. Heart Failure Post-Myocardial Infarction In patients with heart failure post-myocardial infarction who are currently being treated with a diuretic, symptomatic hypotension occasionally can occur following the initial dose of ramipril. If the initial dose of 2.5 mg ramipril cannot be tolerated, use an initial dose of 1.25 mg ramipril to avoid excessive hypotension . Consider reducing the dose of concomitant diuretic to decrease the incidence of hypotension. Congestive Heart Failure In patients with congestive heart failure, with or without associated renal insufficiency, ACE inhibitor therapy may cause excessive hypotension, which may be associated with oliguria or azotemia and rarely, with acute renal failure and death. In such patients, initiate ramipril therapy under close medical supervision and follow patients closely for the first 2 weeks of treatment and whenever the dose of ramipril or diuretic is increased. Surgery and Anesthesia In patients undergoing surgery or during anesthesia with agents that produce hypotension, ramipril may block angiotensin II formation that would otherwise occur secondary to compensatory renin release. Hypotension that occurs as a result of this mechanism can be corrected by volume expansion. 5.6 Fetal Toxicity Pregnancy Category D Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue ramipril as soon as possible [see USE IN SPECIFIC POPULATIONS ( 8.1 ) ]. 5.7 Dual Blockade of the Renin-Angiotensin-Aldosterone System Telmisartan The ONTARGET trial enrolled 25,620 patients >55 years old with atherosclerotic disease or diabetes with end-organ damage, randomized them to telmisartan only, ramipril only, or the combination, and followed them for a median of 56 months. Patients receiving the combination of telmisartan and ramipril did not obtain any benefit in the composite endpoint of cardiovascular death, MI, stroke and heart failure hospitalization compared to monotherapy, but experienced an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, or dialysis) compared with groups receiving telmisartan alone or ramipril alone. Concomitant use of telmisartan and ramipril is not recommended. 5.8 Hyperkalemia In clinical trials with ramipril, hyperkalemia (serum potassium >5.7 mEq/L) occurred in approximately 1% of hypertensive patients receiving ramipril. In most cases, these were isolated values, which resolved despite continued therapy. None of these patients were discontinued from the trials because of hyperkalemia. Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes, which should be used cautiously, if at all, with ramipril [see DRUG INTERACTIONS ( 7.1 ) ]. 5.9 Cough Presumably caused by inhibition of the degradation of endogenous bradykinin, persistent nonproductive cough has been reported with all ACE inhibitors, always resolving after discontinuation of therapy. Consider the possibility of angiotensin converting enzyme inhibitor induced-cough in the differential diagnosis of cough."],"nonclinical_toxicology":["13. NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No evidence of a tumorigenic effect was found when ramipril was given by gavage to rats for up to 24 months at doses of up to 500 mg/kg/day or to mice for up to 18 months at doses of up to 1000 mg/kg/day. (For either species, these doses are about 200 times the maximum recommended human dose when compared on the basis of body surface area.) No mutagenic activity was detected in the Ames test in bacteria, the micronucleus test in mice, unscheduled DNA synthesis in a human cell line, or a forward gene-mutation assay in a Chinese hamster ovary cell line. Several metabolites and degradation products of ramipril were also negative in the Ames test. A study in rats with dosages as great as 500 mg/kg/day did not produce adverse effects on fertility. No teratogenic effects of ramipril were seen in studies of pregnant rats, rabbits, and cynomolgus monkeys. On a body surface area basis, the doses used were up to approximately 400 times (in rats and monkeys) and 2 times (in rabbits) the recommended human dose."],"adverse_reactions_table":["
Table 1. Percentage of Patients with Adverse Events Possibly/ Probably Related to Study Drug—Placebo-Controlled (AIRE) Mortality Study
Adverse Event Placebo (N=982) Ramipril (N=1004)
Hypotension 5% 11%
Cough increased 4% 8%
Dizziness 3% 4%
Angina pectoris 2% 3%
Nausea 1% 2%
Postural hypotension 1% 2%
Syncope 1% 2%
Vomiting 0.5% 2%
Vertigo 0.7% 2%
Abnormal kidney function 0.5% 1%
Diarrhea 0.4% 1%
"],"information_for_patients":["17. PATIENT COUNSELING INFORMATION 17.1 Angioedema Angioedema, including laryngeal edema, can occur rarely with treatment with ACE inhibitors, especially following the first dose. Advise patients to report immediately any signs or symptoms suggesting angioedema (swelling of face, eyes, lips, or tongue, or difficulty in breathing) and to take no more drug until they have consulted with the prescribing physician. 17.2 Neutropenia Advise patients to report promptly any indication of infection (e.g., sore throat, fever), which could be a sign of neutropenia. 17.3 Symptomatic Hypotension Inform patients that light-headedness can occur, especially during the first days of therapy, and it should be reported. Advise patients to discontinue ramipril if syncope (fainting) occurs, and to follow up with their health care providers. Inform patients that inadequate fluid intake or excessive perspiration, diarrhea, or vomiting while taking ramipril can lead to an excessive fall in blood pressure, with the same consequences of lightheadedness and possible syncope. 17.4 Pregnancy Female patients of childbearing age should be told about the consequences of exposure to ramipril during pregnancy. Discuss treatment options with women planning to become pregnant. Patients should be asked to report pregnancies to their physicians as soon as possible. 17.5 Hyperkalemia Advise patients not to use salt substitutes containing potassium without consulting their physician. Manufactured for: Lupin Pharmaceuticals Inc ., Baltimore, Maryland 21202 United States. Manufactured by: Lupin Limited Goa - 403 722 INDIA. Revised: February 15, 2013 ID#: 231272 Repackaged by: Proficient Rx LP Thousand Oaks, CA 91320"],"dosage_and_administration":["2. DOSAGE AND ADMINISTRATION • Hypertension: Initial dose is 2.5 mg to 20 mg once daily. Adjust dosage according to blood pressure response after 2–4 weeks of treatment. The usual maintenance dose following titration is 2.5 mg to 20 mg daily as a single dose or equally divided doses ( 2.1 ). • Heart failure post-myocardial infarction: Starting dose of 2.5 mg twice daily. If patient becomes hypotensive at this dose, decrease dosage to 1.25 mg twice daily. Increase dose as tolerated toward a target dose of 5 mg twice daily, with dosage increases about 3 weeks apart ( 2.3 ). • Dosage adjustment: See respective sections pertaining to dosage adjustment in special situations ( 2.5 ). 2.1 Hypertension The recommended initial dose for patients not receiving a diuretic is 2.5 mg once a day. Adjust dose according to blood pressure response. The usual maintenance dosage range is 2.5 mg to 20 mg per day administered as a single dose or in two equally divided doses. In some patients treated once daily, the antihypertensive effect may diminish toward the end of the dosing interval. In such patients, consider an increase in dosage or twice daily administration. If blood pressure is not controlled with ramipril alone, a diuretic can be added. 2.3 Heart Failure Post-Myocardial Infarction For the treatment of post-myocardial infarction patients who have shown signs of congestive heart failure, the recommended starting dose of ramipril is 2.5 mg twice daily (5 mg per day). A patient who becomes hypotensive at this dose may be switched to 1.25 mg twice daily. After one week at the starting dose, increase dose (if tolerated) toward a target dose of 5 mg twice daily, with dosage increases being about 3 weeks apart. After the initial dose of ramipril, observe the patient under medical supervision for at least two hours and until blood pressure has stabilized for at least an additional hour. If possible, reduce the dose of any concomitant diuretic as this may diminish the likelihood of hypotension. The appearance of hypotension after the initial dose of ramipril does not preclude subsequent careful dose titration with the drug, following effective management of the hypotension [see WARNINGS AND PRECAUTIONS ( 5.5 ) , DRUG INTERACTIONS ( 7.1 ) ]. 2.4 General Dosing Information Generally, swallow ramipril capsules whole. The ramipril capsule can also be opened and the contents sprinkled on a small amount (about 4 oz.) of applesauce or mixed in 4 oz. (120 mL) of water or apple juice. To be sure that ramipril is not lost when such a mixture is used, consume the mixture in its entirety. The described mixtures can be pre-prepared and stored for up to 24 hours at room temperature or up to 48 hours under refrigeration. Concomitant administration of ramipril with potassium supplements, potassium salt substitutes, or potassium-sparing diuretics can lead to increases of serum potassium [see WARNINGS AND PRECAUTIONS ( 5.8 ) ] . 2.5 Dosage Adjustment Renal Impairment Establish baseline renal function in patients initiating ramipril capsules. Usual regimens of therapy with ramipril capsule may be followed in patients with estimated creatinine clearance >40 mL/min. However, in patients with worse impairment, 25 % of the usual dose of ramipril capsule is expected to produce full therapeutic levels of ramiprilat [see USE IN SPECIFIC POPULATIONS ( Error! Hyperlink reference not valid.) ]. Hypertension For patients with hypertension and renal impairment, the recommended initial dose is 1.25 mg ramipril once daily. Dosage may be titrated upward until blood pressure is controlled or to a maximum total daily dose of 5 mg. Heart Failure Post-Myocardial Infarction For patients with heart failure and renal impairment, the recommended initial dose is 1.25 mg ramipril once daily. The dose may be increased to 1.25 mg twice daily, and up to a maximum dose of 2.5 mg twice daily depending on clinical response and tolerability. Volume Depletion or Renal Artery Stenosis Blood pressure decreases associated with any dose of ramipril depend, in part, on the presence or absence of volume depletion (e.g., past and current diuretic use) or the presence or absence of renal artery stenosis. If such circumstances are suspected to be present, initiate dosing at 1.25 mg once daily. Adjust dosage according to blood pressure response."],"spl_product_data_elements":["Ramipril Ramipril RAMIPRIL RAMIPRILAT FD&C BLUE NO. 1 FD&C RED NO. 40 GELATIN, UNSPECIFIED MEGLUMINE STARCH, CORN TITANIUM DIOXIDE LUPIN;RAMIPRIL;5;mg Ramipril Ramipril RAMIPRIL RAMIPRILAT FD&C BLUE NO. 1 GELATIN, UNSPECIFIED MEGLUMINE STARCH, CORN TITANIUM DIOXIDE Light Blue LUPIN;RAMIPRIL;10;mg"],"dosage_forms_and_strengths":["3. DOSAGE FORMS AND STRENGTHS Capsule: 1.25 mg, 2.5 mg, 5 mg, 10 mg ( 3 ) Ramipril capsules USP are supplied as hard gelatin capsules containing 1.25 mg, 2.5 mg, 5 mg, and 10 mg of ramipril."],"use_in_specific_populations":["8. USE IN SPECIFIC POPULATIONS • Pregnancy: Discontinue drug if pregnancy is detected ( 5.6 , 8.1 ). • Nursing mothers: Ramipril use is not recommended in nursing mothers ( 8.3 ). 8.1 Pregnancy Pregnancy Category D Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue ramipril as soon as possible. These adverse outcomes are usually associated with use of these drugs in the second and third trimester of pregnancy. Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. Appropriate management of maternal hypertension during pregnancy is important to optimize outcomes for both mother and fetus. In the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus. Perform serial ultrasound examinations to assess the intra-amniotic environment. If oligohydramnios is observed, discontinue ramipril unless it is considered life-saving for the mother. Fetal testing may be appropriate, based on the week of pregnancy. Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury. Closely observe infants with histories of in utero exposure to ramipril for hypotension, oliguria, and hyperkalemia [see USE IN SPECIFIC POPULATIONS ( 8.4 ) ]. 8.3 Nursing Mothers Ingestion of a single 10 mg oral dose of ramipril resulted in undetectable amounts of ramipril and its metabolites in breast milk. However, because multiple doses may produce low milk concentrations that are not predictable from a single dose, do not use ramipril in nursing mothers. 8.4 Pediatric Use Neonates with a history of in utero exposure to ramipril If oliguria or hypotension occurs, direct attention toward support of blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing hypotension and/or substituting for disordered renal function. Ramipril, which crosses the placenta, can theoretically be removed from the neonatal circulation by these means, but limited experience has not shown that such removal is central to the treatment of these infants. Safety and effectiveness in pediatric patients have not been established. Irreversible kidney damage has been observed in very young rats given a single dose of ramipril. 8.5 Geriatric Use Of the total number of patients who received ramipril in U.S. clinical studies of ramipril, 11.0% were ≥65 years of age while 0.2% were ≥75 years of age. No overall differences in effectiveness or safety were observed between these patients and younger patients, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but a greater sensitivity of some older individuals cannot be ruled out. One pharmacokinetic study conducted in hospitalized elderly patients indicated that peak ramiprilat levels and area under the plasma concentration-time curve (AUC) for ramiprilat are higher in older patients. 8.6 Renal Impairment A single-dose pharmacokinetic study was conducted in hypertensive patients with varying degrees of renal impairment who received a single 10 mg dose of ramipril. Patients were stratified into four groups based on initial estimates of creatinine clearance: normal (>80 mL/min), mild impairment (40 to 80 mL/min), moderate impairment (15 to 40 mL/min), and severe impairment (<15 mL/min). On average, the AUC 0-24h for ramiprilat was approximately 1.7-fold higher, 3.0-fold higher, and 3.2-fold higher in the groups with mild, moderate, and severe renal impairment, respectively, compared to the group with normal renal function. Over all, the results suggest that the starting dose of ramipril should be adjusted downward in patients with moderate-to-severe renal impairment."],"package_label_principal_display_panel":["PACKAGE LABEL.PRINCIPAL DISPLAY PANEL 63187-073-30","Package/Label Display Panel 63187-277-30"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No evidence of a tumorigenic effect was found when ramipril was given by gavage to rats for up to 24 months at doses of up to 500 mg/kg/day or to mice for up to 18 months at doses of up to 1000 mg/kg/day. (For either species, these doses are about 200 times the maximum recommended human dose when compared on the basis of body surface area.) No mutagenic activity was detected in the Ames test in bacteria, the micronucleus test in mice, unscheduled DNA synthesis in a human cell line, or a forward gene-mutation assay in a Chinese hamster ovary cell line. Several metabolites and degradation products of ramipril were also negative in the Ames test. A study in rats with dosages as great as 500 mg/kg/day did not produce adverse effects on fertility. No teratogenic effects of ramipril were seen in studies of pregnant rats, rabbits, and cynomolgus monkeys. On a body surface area basis, the doses used were up to approximately 400 times (in rats and monkeys) and 2 times (in rabbits) the recommended human dose."]},"tags":[{"label":"Angiotensin Converting Enzyme Inhibitor","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Angiotensin-converting enzyme","category":"target"},{"label":"ACE","category":"gene"},{"label":"C09AA05","category":"atc"},{"label":"ORAL","category":"route"},{"label":"oral","category":"route"},{"label":"Capsule","category":"form"},{"label":"Tablet","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Cerebrovascular accident","category":"indication"},{"label":"Chronic heart failure","category":"indication"},{"label":"Hypertensive disorder","category":"indication"},{"label":"Left ventricular cardiac dysfunction","category":"indication"},{"label":"Myocardial Infarction Prevention","category":"indication"},{"label":"King Pfizer","category":"company"},{"label":"Approved 1990s","category":"decade"},{"label":"Angiotensin-Converting Enzyme Inhibitors","category":"pharmacology"},{"label":"Antihypertensive Agents","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Protease Inhibitors","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":["WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning • When pregnancy is detected, discontinue ramipril as soon as possible ( 5.6 ). • Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus ( 5.6 ). WARNING: FETAL TOXICITY • When pregnancy is detected, discontinue ramipril as soon as possible ( 5.6 ). • Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus ( 5.6 )."],"safetySignals":[{"llr":1774.564,"date":"","count":5780,"signal":"Acute kidney injury","source":"DrugCentral FAERS","actionTaken":"Reported 5,780 times (LLR=1775)"},{"llr":1193.152,"date":"","count":1945,"signal":"Hyperkalaemia","source":"DrugCentral FAERS","actionTaken":"Reported 1,945 times (LLR=1193)"},{"llr":1074.445,"date":"","count":3362,"signal":"General physical health deterioration","source":"DrugCentral FAERS","actionTaken":"Reported 3,362 times (LLR=1074)"},{"llr":847.721,"date":"","count":1366,"signal":"Angioedema","source":"DrugCentral FAERS","actionTaken":"Reported 1,366 times (LLR=848)"},{"llr":761.009,"date":"","count":3529,"signal":"Drug ineffective","source":"DrugCentral FAERS","actionTaken":"Reported 3,529 times (LLR=761)"},{"llr":706.442,"date":"","count":1385,"signal":"Death","source":"DrugCentral FAERS","actionTaken":"Reported 1,385 times (LLR=706)"},{"llr":693.347,"date":"","count":2060,"signal":"Hyponatraemia","source":"DrugCentral FAERS","actionTaken":"Reported 2,060 times (LLR=693)"},{"llr":604.034,"date":"","count":2060,"signal":"Syncope","source":"DrugCentral FAERS","actionTaken":"Reported 2,060 times (LLR=604)"},{"llr":601.178,"date":"","count":1647,"signal":"Bradycardia","source":"DrugCentral FAERS","actionTaken":"Reported 1,647 times (LLR=601)"},{"llr":596.443,"date":"","count":342,"signal":"Product dose omission issue","source":"DrugCentral FAERS","actionTaken":"Reported 342 times (LLR=596)"},{"llr":574.482,"date":"","count":3538,"signal":"Drug interaction","source":"DrugCentral FAERS","actionTaken":"Reported 3,538 times (LLR=574)"},{"llr":572.25,"date":"","count":3721,"signal":"Hypotension","source":"DrugCentral FAERS","actionTaken":"Reported 3,721 times (LLR=572)"},{"llr":549.606,"date":"","count":583,"signal":"Hypertensive crisis","source":"DrugCentral FAERS","actionTaken":"Reported 583 times (LLR=550)"},{"llr":547.024,"date":"","count":152,"signal":"Completed suicide","source":"DrugCentral FAERS","actionTaken":"Reported 152 times (LLR=547)"},{"llr":512.6,"date":"","count":821,"signal":"Product prescribing error","source":"DrugCentral FAERS","actionTaken":"Reported 821 times (LLR=513)"}],"drugInteractions":[{"url":"/drug/spironolactone","drug":"spironolactone","action":"Monitor closely","effect":"May interact with Spironolactone","source":"DrugCentral","drugSlug":"spironolactone"},{"url":"/drug/triamterene","drug":"triamterene","action":"Monitor closely","effect":"May interact with Triamterene","source":"DrugCentral","drugSlug":"triamterene"}],"commonSideEffects":[{"effect":"Cough","drugRate":"12%","severity":"common","_validated":true},{"effect":"Asthenia (Fatigue)","drugRate":"2%","severity":"mild","_validated":true},{"effect":"Upper respiratory infection","drugRate":"reported","severity":"unknown"},{"effect":"Flu syndrome","drugRate":"reported","severity":"unknown"},{"effect":"Anaphylactoid reactions","drugRate":"reported","severity":"unknown"},{"effect":"Symptomatic hypotension","drugRate":"0.5%","severity":"mild","_validated":true},{"effect":"Syncope","drugRate":"reported","severity":"unknown"},{"effect":"Palpitations","drugRate":"reported","severity":"unknown"},{"effect":"Pancytopenia","drugRate":"reported","severity":"unknown"},{"effect":"Hemolytic anemia","drugRate":"reported","severity":"unknown"},{"effect":"Thrombocytopenia","drugRate":"reported","severity":"unknown"},{"effect":"Acute renal failure","drugRate":"reported","severity":"unknown"},{"effect":"Angioneurotic edema","drugRate":"0.3%","severity":"mild","_validated":true},{"effect":"Hepatic failure","drugRate":"reported","severity":"unknown"},{"effect":"Hepatitis","drugRate":"reported","severity":"unknown"},{"effect":"Jaundice","drugRate":"reported","severity":"unknown"},{"effect":"Pancreatitis","drugRate":"reported","severity":"unknown"},{"effect":"Abdominal pain","drugRate":"reported","severity":"unknown"},{"effect":"Anorexia","drugRate":"reported","severity":"unknown"},{"effect":"Constipation","drugRate":"reported","severity":"unknown"},{"effect":"Diarrhea","drugRate":"reported","severity":"unknown"},{"effect":"Dry mouth","drugRate":"reported","severity":"unknown"},{"effect":"Dyspepsia","drugRate":"reported","severity":"unknown"},{"effect":"Dysphagia","drugRate":"reported","severity":"unknown"},{"effect":"Gastroenteritis","drugRate":"reported","severity":"unknown"},{"effect":"Increased salivation","drugRate":"reported","severity":"unknown"},{"effect":"Taste disturbance","drugRate":"reported","severity":"unknown"},{"effect":"Apparent hypersensitivity reactions","drugRate":"reported","severity":"unknown"},{"effect":"Photosensitivity","drugRate":"reported","severity":"unknown"},{"effect":"Purpura","drugRate":"reported","severity":"unknown"}],"contraindications":["Acute vomiting","Azotemia","Dehydration","Disease of liver","Disorder of connective tissue","Head and Neck Angioedema","Hereditary angioneurotic edema","Hyperkalemia","Hyponatremia","Hyposensitization to allergens","Intestinal Angioedema","Kidney disease","Liver function tests abnormal","Low blood pressure","Neutropenic disorder","Oliguria","Pregnancy, function","Renal artery stenosis","Renal dialysis","Severe diarrhea","Systemic lupus erythematosus","Systemic sclerosis"],"specialPopulations":{"Pregnancy":"Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue ramipril as soon as possible. These adverse outcomes are usually associated with use of these drugs in the second and third trimester of pregnancy. Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. Appropriate management of maternal hypertension during pregnancy is important to optimize outcomes for both mother and fetus.In the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for particular patient, apprise the mother of the potential risk to the fetus. Perform serial ultrasound examinations to assess the intra-amniotic environment. If oligohydramnios is observed, discontinue ramipril unless it is considered life-saving for the mother. Fetal testing may be appropriate, based on the week of pregnancy. Patients and physicians should be aware, however, that","Geriatric use":"Of the total number of patients who received ramipril in US clinical studies of ramipril 11.0% were 65 and over while 0.2% were 75 and over. No overall differences in effectiveness or safety were observed between these patients and younger patients, and other, reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. One pharmacokinetic study conducted in","Paediatric use":"If oliguria or hypotension occurs, direct attention toward support of blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as means of reversing hypotension and/or substituting for disordered renal function. Ramipril, which crosses the placenta, can be removed from the neonatal circulation by these means, but limited experience has not shown that such removal is central to the treatment of the"}},"trials":[],"aliases":[],"company":"King Pfizer","patents":[{"type":"Formulation","number":"12343338","applicant":"ROSEMONT PHARMACEUTICALS HOLDINGS INC","territory":"US","tradeName":"VOSTALLY","expiryDate":"2039-08-16"}],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.1042/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$38","description":"RAMIPRIL 1.25 MG CAPSULE","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=RAMIPRIL","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T05:56:42.064130+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T05:56:42.063798+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T05:56:48.728140+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=RAMIPRIL","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T05:56:49.503786+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T05:56:39.983429+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T05:56:39.983463+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (boxed_warning)","rawText":"WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning • When pregnancy is detected, discontinue ramipril as soon as possible ( 5.6 ). • Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus ( 5.6 ). WARNING: FETAL TOXICITY • When pregnancy is detected, discontinue ramipril as soon as possible ( 5.6 ). • Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus ( 5.6","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T05:56:39.983474+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Angiotensin-converting enzyme inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:56:50.050347+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1168/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:56:49.960950+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA077626","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T05:56:39.983480+00:00"}},"allNames":"altace","offLabel":[],"synonyms":["HOE498","HOE-498","ramipril"],"timeline":[{"date":"1991-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from KING PHARMS to King Pfizer"},{"date":"2014-04-15","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 16 manufacturers approved"},{"date":"2025-07-23","type":"positive","source":"FDA Orange Book","milestone":"Vostally approved — 1MG/ML"}],"approvals":[{"date":"1991-01-28","orphan":false,"company":"KING PHARMS","regulator":"FDA"}],"brandName":"Altace","ecosystem":[{"indication":"Cerebrovascular accident","otherDrugs":[{"name":"amlodipine","slug":"amlodipine","company":"Pfizer"},{"name":"atorvastatin","slug":"atorvastatin","company":"Pfizer"},{"name":"pravastatin","slug":"pravastatin","company":"Bristol Myers Squibb"},{"name":"rosuvastatin","slug":"rosuvastatin","company":"Ipr"}],"globalPrevalence":101000000},{"indication":"Chronic heart failure","otherDrugs":[{"name":"candesartan cilexetil","slug":"candesartan-cilexetil","company":"Astrazeneca"},{"name":"captopril","slug":"captopril","company":"Par Pharm"},{"name":"carvedilol","slug":"carvedilol","company":"Smithkline Beecham"},{"name":"chlorothiazide","slug":"chlorothiazide","company":"Oak Pharms Akorn"}],"globalPrevalence":64000000},{"indication":"Hypertensive disorder","otherDrugs":[{"name":"acebutolol","slug":"acebutolol","company":"Promius Pharma"},{"name":"aliskiren","slug":"aliskiren","company":"Novartis"},{"name":"amiloride","slug":"amiloride","company":"Paddock Llc"},{"name":"amlodipine","slug":"amlodipine","company":"Pfizer"}],"globalPrevalence":null},{"indication":"Left ventricular cardiac dysfunction","otherDrugs":[{"name":"captopril","slug":"captopril","company":"Par Pharm"},{"name":"carvedilol","slug":"carvedilol","company":"Smithkline Beecham"},{"name":"glyceryl trinitrate","slug":"glyceryl-trinitrate","company":"Fougera"},{"name":"trandolapril","slug":"trandolapril","company":"Abbvie"}],"globalPrevalence":null},{"indication":"Myocardial Infarction Prevention","otherDrugs":[{"name":"amlodipine","slug":"amlodipine","company":"Pfizer"},{"name":"atorvastatin","slug":"atorvastatin","company":"Pfizer"},{"name":"lovastatin","slug":"lovastatin","company":"Merck"},{"name":"perindopril","slug":"perindopril","company":"Symplmed Pharms Llc"}],"globalPrevalence":523000000}],"mechanism":{"target":"Angiotensin-converting enzyme","novelty":"Follow-on","targets":[{"gene":"ACE","source":"DrugCentral","target":"Angiotensin-converting enzyme","protein":"Angiotensin-converting enzyme"}],"moaClass":"Angiotensin-converting Enzyme Inhibitors","modality":"Small Molecule","drugClass":"Angiotensin Converting Enzyme Inhibitor [EPC]","explanation":"Mechanism of Action. Ramipril and ramiprilat inhibit angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is peptidyl dipeptidase that catalyzes the conversion of angiotensin to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. Inhibition of ACE results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and to decreased aldosterone secretion. The latter decrease may result in small increase of serum potassium. In hypertensive patients with normal renal function treated with ramipril alone for up to 56 weeks, approximately 4% of patients during the trial had an abnormally high serum potassium and an increase from baseline greater than 0.75 mEq/L, and none of the patients had an abnormally low potassium and decrease from baseline greater than 0.75 mEq/L. In the same study, approximately 2% of patients treated with ramipril and hydrochlorothiazide for up to 56 weeks ha","oneSentence":"Altace works by blocking the action of angiotensin-converting enzyme, a key player in the renin-angiotensin-aldosterone system that regulates blood pressure.","technicalDetail":"Altace inhibits the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, thereby reducing peripheral resistance and lowering blood pressure."},"commercial":{"launchDate":"1991","_launchSource":"DrugCentral (FDA 1991-01-28, KING PHARMS)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2356","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=RAMIPRIL","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=RAMIPRIL","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T15:30:36.397736","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T05:56:56.397417+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"captopril","drugSlug":"captopril","fdaApproval":"1981-04-06","genericCount":21,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"enalapril","drugSlug":"enalapril","fdaApproval":"1985-12-24","patentExpiry":"Nov 6, 2032","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"lisinopril","drugSlug":"lisinopril","fdaApproval":"1987-12-29","patentExpiry":"Nov 6, 2035","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"perindopril","drugSlug":"perindopril","fdaApproval":"1993-12-30","genericCount":5,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"quinapril","drugSlug":"quinapril","fdaApproval":"1991-11-19","genericCount":12,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"benazepril","drugSlug":"benazepril","fdaApproval":"1991-06-25","genericCount":12,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"fosinopril","drugSlug":"fosinopril","fdaApproval":"1991-05-16","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"trandolapril","drugSlug":"trandolapril","fdaApproval":"1996-04-26","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"spirapril","drugSlug":"spirapril","fdaApproval":"1994-12-29","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"moexipril","drugSlug":"moexipril","fdaApproval":"1995-04-19","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"ramipril","indications":{"approved":[{"name":"Cerebrovascular accident","source":"DrugCentral","snomedId":230690007,"regulator":"FDA","eligibility":"Not explicitly mentioned, but likely not applicable as it's a condition being treated, not an indication","usPrevalence":null,"globalPrevalence":101000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Chronic heart failure","source":"DrugCentral","snomedId":48447003,"regulator":"FDA","eligibility":"Not explicitly mentioned, but likely not applicable as it's a condition being treated, not an indication","usPrevalence":6200000,"globalPrevalence":64000000,"prevalenceMethod":"curated","prevalenceSource":"ESC Heart Failure, 2023"},{"name":"Hypertensive disorder","source":"DrugCentral","snomedId":38341003,"regulator":"FDA","eligibility":"Not explicitly mentioned, but likely not applicable as it's a condition being treated, not an indication"},{"name":"Left ventricular cardiac dysfunction","source":"DrugCentral","snomedId":429589006,"regulator":"FDA","eligibility":"Not explicitly mentioned, but likely not applicable as it's a condition being treated, not an indication"},{"name":"Myocardial Infarction Prevention","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Stable patients who have demonstrated clinical signs of congestive heart failure within the first few days after sustaining acute myocardial infarction","usPrevalence":null,"globalPrevalence":523000000,"prevalenceMethod":"curated","prevalenceSource":"WHO CVD Factsheet, 2023"}],"offLabel":[{"name":"Acute scleroderma renal crisis","source":"DrugCentral","drugName":"RAMIPRIL"},{"name":"Atrial fibrillation","source":"DrugCentral","drugName":"RAMIPRIL"},{"name":"Diabetic renal disease","source":"DrugCentral","drugName":"RAMIPRIL"},{"name":"Diastolic heart failure","source":"DrugCentral","drugName":"RAMIPRIL","evidenceCount":56,"evidenceLevel":"strong"},{"name":"Hypertension due to Scleroderma","source":"DrugCentral","drugName":"RAMIPRIL"},{"name":"Nondiabetic Proteinuric Nephropathy","source":"DrugCentral","drugName":"RAMIPRIL","evidenceCount":13,"evidenceLevel":"moderate"}],"pipeline":[]},"currentOwner":"King Pfizer","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"captopril","brandName":"captopril","genericName":"captopril","approvalYear":"1981","relationship":"same-class"},{"drugId":"enalapril","brandName":"enalapril","genericName":"enalapril","approvalYear":"1985","relationship":"same-class"},{"drugId":"lisinopril","brandName":"lisinopril","genericName":"lisinopril","approvalYear":"1987","relationship":"same-class"},{"drugId":"perindopril","brandName":"perindopril","genericName":"perindopril","approvalYear":"1993","relationship":"same-class"},{"drugId":"quinapril","brandName":"quinapril","genericName":"quinapril","approvalYear":"1991","relationship":"same-class"},{"drugId":"benazepril","brandName":"benazepril","genericName":"benazepril","approvalYear":"1991","relationship":"same-class"},{"drugId":"fosinopril","brandName":"fosinopril","genericName":"fosinopril","approvalYear":"1991","relationship":"same-class"},{"drugId":"trandolapril","brandName":"trandolapril","genericName":"trandolapril","approvalYear":"1996","relationship":"same-class"},{"drugId":"spirapril","brandName":"spirapril","genericName":"spirapril","approvalYear":"1994","relationship":"same-class"},{"drugId":"moexipril","brandName":"moexipril","genericName":"moexipril","approvalYear":"1995","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07045038","phase":"NA","title":"Blood Flow Restricted Resistance Exercises Versus Low Level Laser on Cardiac Functions in Patients With Chronic Heart Failure","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cairo University","startDate":"2025-01-20","conditions":["Heart Failure NYHA Class II"],"enrollment":60,"completionDate":"2026-04"},{"nctId":"NCT03475186","phase":"PHASE2","title":"Testing Ramipril to Prevent Memory Loss in People With Glioblastoma","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2019-03-25","conditions":["Glioblastoma","Radiotherapy; Complications","Cognitive Decline","Chemoradiation"],"enrollment":75,"completionDate":"2025-03-25"},{"nctId":"NCT07099677","phase":"NA","title":"Short-Term Effects of Antihypertensive Drugs on Postural Balance and Fall Risk","status":"RECRUITING","sponsor":"Abant Izzet Baysal University","startDate":"2025-08-01","conditions":["Hypertension","Fall Risk","Postural Balance","Fear of Falling"],"enrollment":186,"completionDate":"2026-06-30"},{"nctId":"NCT04591210","phase":"PHASE3","title":"The COVID-RASi Trial (COVID-19)","status":"COMPLETED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2021-01-27","conditions":["COVID-19","Cardiovascular Diseases"],"enrollment":372,"completionDate":"2024-12-30"},{"nctId":"NCT07315139","phase":"NA","title":"Pentoxifylline on Inflammatory Markers in Non-Diabetic Chronic Kidney Disease Patients","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-02-01","conditions":["Pentoxifylline","Inflammatory Markers","Non-Diabetic","Chronic Kidney Disease"],"enrollment":42,"completionDate":"2023-08-31"},{"nctId":"NCT01037530","phase":"PHASE4","title":"Clinical and Cost Effectiveness of ACE Inhibitor, Ramipril, in Intermittent Claudicants","status":"COMPLETED","sponsor":"Hull University Teaching Hospitals NHS Trust","startDate":"2010-12","conditions":["Intermittent Claudicants"],"enrollment":33,"completionDate":"2012-12"},{"nctId":"NCT07259512","phase":"PHASE4","title":"Single and Twice-daily Dosing of Ramipril on Renal Function in Chronic Kidney Disease Patients With Reduced Ejection Fraction Heart Failure","status":"RECRUITING","sponsor":"Evi Liliek Wulandari","startDate":"2025-06-30","conditions":["Chronic Kidney Disease","Heart Failure With Reduced Ejection Fraction (HFrEF)"],"enrollment":80,"completionDate":"2026-01-31"},{"nctId":"NCT05963568","phase":"PHASE3","title":"Stroke Minimization Through Additive Anti-atherosclerotic Agents in Routine Treatment II Study (SMAART II)","status":"NOT_YET_RECRUITING","sponsor":"Northern California Institute of Research and Education","startDate":"2026-01-01","conditions":["Stroke","Medication Adherence"],"enrollment":680,"completionDate":"2028-09-01"},{"nctId":"NCT07262710","phase":"","title":"Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","startDate":"2025-12-01","conditions":["Post-stroke Pneumonia"],"enrollment":13656,"completionDate":"2026-08-19"},{"nctId":"NCT04983823","phase":"NA","title":"Persistent Cardiovascular Effects of COVID-19 Viral Infection Trial (PERCEIVE)","status":"RECRUITING","sponsor":"Baker Heart and Diabetes Institute","startDate":"2021-11-18","conditions":["Heart Failure"],"enrollment":820,"completionDate":"2025-12-30"},{"nctId":"NCT07184918","phase":"NA","title":"Effect of Continuing vs. Discontinuing ACE Inhibitors on Renal Function After Coronary Angiography","status":"COMPLETED","sponsor":"Tanta University","startDate":"2024-02-01","conditions":["Contrast-Induced Nephropathy","Coronary Angiography","Acute Kidney Injury"],"enrollment":44,"completionDate":"2025-06-01"},{"nctId":"NCT05030818","phase":"PHASE4","title":"Cross-over Study of Coronary Risk Factors With a Polypill","status":"RECRUITING","sponsor":"Fundación EPIC","startDate":"2022-10-14","conditions":["Coronary Artery Disease"],"enrollment":88,"completionDate":"2026-04-30"},{"nctId":"NCT06562582","phase":"PHASE4","title":"STunning in Acute Myocardial Infarction - BAS","status":"RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2025-01-06","conditions":["Myocardial Infarct"],"enrollment":120,"completionDate":"2027-12-31"},{"nctId":"NCT05942053","phase":"PHASE4","title":"Role of Vitamin K2 in Chronic Kidney Disease","status":"RECRUITING","sponsor":"Tanta University","startDate":"2023-07-15","conditions":["Chronic Kidney Diseases"],"enrollment":44,"completionDate":"2026-07-15"},{"nctId":"NCT07023016","phase":"PHASE2,PHASE3","title":"Comparative Assessment of Efficacy & Safety of Sacubitril/Valsartan Versus Ramipril in Patients With Renal Dysfunction Hospitalized With Acute Decompensated Heart Failure","status":"COMPLETED","sponsor":"National Heart Institute, Egypt","startDate":"2023-11-01","conditions":["Acute Decompensated Heart Failure (ADHF)","Chronic Kidney Disease (CKD)"],"enrollment":515,"completionDate":"2025-02-28"},{"nctId":"NCT05942027","phase":"PHASE4","title":"Role of Coenzyme Q10 in Chronic Kidney Disease","status":"RECRUITING","sponsor":"Tanta University","startDate":"2023-07-15","conditions":["Chronic Kidney Diseases"],"enrollment":44,"completionDate":"2026-07-15"},{"nctId":"NCT07027774","phase":"PHASE4","title":"Effect of Henagliflozin on Renal Outcomes in Non-dialysis Patients With Advanced Chronic Kidney Disease : A Multicenter Prospective, Randomized Controlled Trial（HERO -aCKD）","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wannan Medical College","startDate":"2025-07-10","conditions":["Chronic Kidney Disease Stage 4"],"enrollment":429,"completionDate":"2027-12-30"},{"nctId":"NCT03440177","phase":"","title":"Bariatric Surgery and Pharmacokinetics of Ramipril","status":"RECRUITING","sponsor":"Norwegian University of Science and Technology","startDate":"2018-01-02","conditions":["Obesity, Morbid"],"enrollment":12,"completionDate":"2026-12"},{"nctId":"NCT04962711","phase":"NA","title":"Risk-guided Disease Management Plan to Prevent Heart Failure in Patients Treated With Previous Chemotherapy (REDEEM)","status":"RECRUITING","sponsor":"Baker Heart and Diabetes Institute","startDate":"2023-03-30","conditions":["Heart Failure"],"enrollment":685,"completionDate":"2025-12-31"},{"nctId":"NCT02596126","phase":"PHASE3","title":"Secondary Prevention of Cardiovascular Disease in the Elderly Trial","status":"COMPLETED","sponsor":"Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III","startDate":"2016-07","conditions":["Myocardial Infarction","Cardiovascular Disease"],"enrollment":2499,"completionDate":"2022-03-31"},{"nctId":"NCT02842424","phase":"PHASE4","title":"Ramipril Treatment of Claudication: Oxidative Damage and Muscle Fibrosis","status":"RECRUITING","sponsor":"University of Nebraska","startDate":"2016-02-25","conditions":["Peripheral Arterial Disease"],"enrollment":70,"completionDate":"2026-06"},{"nctId":"NCT06104423","phase":"PHASE4","title":"Open-label inteRventional Clinical Trial to Assess Efficacy and Safety of the exteMporaneous combInation of Nebivolol and Ramipril in hypertenSIve pAtients","status":"COMPLETED","sponsor":"Menarini International Operations Luxembourg SA","startDate":"2023-10-02","conditions":["Hypertension"],"enrollment":266,"completionDate":"2024-02-19"},{"nctId":"NCT05637853","phase":"PHASE4","title":"Telemonitored Fast Track Medical Sequencing for Heart Failure With Reduced Ejection Fraction","status":"ACTIVE_NOT_RECRUITING","sponsor":"Göteborg University","startDate":"2022-10-22","conditions":["Heart Failure With Reduced Ejection Fraction"],"enrollment":60,"completionDate":"2026-08-26"},{"nctId":"NCT04662723","phase":"PHASE4","title":"Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.","status":"RECRUITING","sponsor":"Fondazione Schena","startDate":"2023-05-01","conditions":["Glomerulonephritis","Immunoglobulin A Nephropathy"],"enrollment":878,"completionDate":"2028-12-31"},{"nctId":"NCT04173949","phase":"PHASE3","title":"Explorative Study for Treating Persistent Developmental Stuttering With Ramipril","status":"ACTIVE_NOT_RECRUITING","sponsor":"HaEmek Medical Center, Israel","startDate":"2020-03-15","conditions":["Persistent Developmental Stuttering"],"enrollment":10,"completionDate":"2025-12-30"},{"nctId":"NCT02901977","phase":"PHASE4","title":"Doxazosin and Ramipril in Hypertension","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2011-03","conditions":["Hypertension"],"enrollment":71,"completionDate":"2015-04"},{"nctId":"NCT05498675","phase":"","title":"Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study","status":"RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2021-09-01","conditions":["Sacubitril/Valsartan","Hypertension","Obesity"],"enrollment":180,"completionDate":"2027-06-30"},{"nctId":"NCT00933231","phase":"PHASE3","title":"Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-08-17","conditions":["Kidney Transplantation"],"enrollment":281,"completionDate":"2018-04-03"},{"nctId":"NCT05508035","phase":"PHASE3","title":"The Effect of Sacubitril/valsartan Versus Ramipril on Left Ventricular Function and Remodeling in Patients with Ischemic Heart Failure with Mid-range Ejection Fraction","status":"RECRUITING","sponsor":"John Paul II Hospital, Krakow","startDate":"2023-07-13","conditions":["Heart Failure with Moderately Reduced Ejection Fraction"],"enrollment":666,"completionDate":"2027-06"},{"nctId":"NCT05849766","phase":"PHASE3","title":"Effect of Dapagliflozin on Cardiac Structure, Function and Secondary Mitral Regurgitation in Patients with Left Ventricle Dysfunction","status":"COMPLETED","sponsor":"October 6 University","startDate":"2023-04-27","conditions":["Dilated Cardiomyopathy"],"enrollment":150,"completionDate":"2024-09-01"},{"nctId":"NCT00829452","phase":"PHASE1","title":"Ramipril 10 mg Capsule in Healthy Subjects Under Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2004-08","conditions":["Healthy"],"enrollment":40,"completionDate":"2004-10"},{"nctId":"NCT00828321","phase":"PHASE1","title":"Ramipril 10 mg Capsule in Healthy Subjects Under Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2004-08","conditions":["Healthy"],"enrollment":40,"completionDate":"2004-10"},{"nctId":"NCT00829530","phase":"PHASE1","title":"Ramipril 10 mg Capsule in Healthy Subjects Under Fed Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2004-08","conditions":["Healthy"],"enrollment":40,"completionDate":"2004-10"},{"nctId":"NCT00480805","phase":"PHASE3","title":"HYZAAR vs. Ramipril for Diabetes (0954A-245)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-08-08","conditions":["Type 2 Diabetes Mellitus","Hypertension"],"enrollment":312,"completionDate":"2002-10-16"},{"nctId":"NCT05122780","phase":"PHASE4","title":"Prognostic Value of Precision Medicine in Patients With MINOCA (PROMISE Trial).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2021-07-01","conditions":["Myocardial Infarction With Non-Obstructive Coronary Arteries"],"enrollment":120,"completionDate":"2025-07"},{"nctId":"NCT06515678","phase":"","title":"Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Hospitalier Pitie-Salpetriere","startDate":"2024-05-20","conditions":["Ovarian Cancer","Antiangiogenic-Associated Hypertension","Adjuvant Bevacizumab","Hypertension"],"enrollment":9464,"completionDate":"2024-08-31"},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":["Community-acquired Pneumonia, Influenza, COVID-19"],"enrollment":20000,"completionDate":"2028-02"},{"nctId":"NCT02008786","phase":"PHASE4","title":"Statin and Angiotensin-converting Enzyme Inhibitor on Symptoms in Patients With SCAD","status":"TERMINATED","sponsor":"Cardiology Research UBC","startDate":"2014-06","conditions":["Coronary Artery Dissection, Spontaneous"],"enrollment":18,"completionDate":"2019-09-13"},{"nctId":"NCT06304896","phase":"PHASE1","title":"Colchicine Versus Beta-blockers, Angiotensin-converting Enzyme Inhibitors, and Statins for Prevention of Chemotherapy-Induced Cardiomyopathy","status":"NOT_YET_RECRUITING","sponsor":"Arab Contractors Medical Centre","startDate":"2024-05-01","conditions":["Chemotherapy Induced Systolic Dysfunction"],"enrollment":150,"completionDate":"2025-12-01"},{"nctId":"NCT05685277","phase":"PHASE1","title":"Bioequivalence Study of Two Formulations of Tablets Ramipril/Hydrochlorothiazide 10 mg/25 mg in Healthy Volunteers Under Fasting Conditions","status":"COMPLETED","sponsor":"Pharmtechnology LLC","startDate":"2022-12-28","conditions":["Bioequivalence"],"enrollment":50,"completionDate":"2023-07-31"},{"nctId":"NCT06187493","phase":"NA","title":"Treatment of Patients With Diabetic Kidney Disease","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2024-01-01","conditions":["Diabetic Kidney Disease"],"enrollment":70,"completionDate":"2025-12-31"},{"nctId":"NCT00274599","phase":"PHASE4","title":"PROBE Investigation of the Safety & Efficacy of Telmisartan (Micardis®) vs Ramipril (Altace®) Using ABPM in HTN","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-10-09","conditions":["Hypertension"],"enrollment":812,"completionDate":""},{"nctId":"NCT04366050","phase":"PHASE2","title":"Ramipril for the Treatment of COVID-19","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2020-05-11","conditions":["COVID-19"],"enrollment":160,"completionDate":"2021-05-12"},{"nctId":"NCT01669434","phase":"PHASE4","title":"Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2015-06-01","conditions":["Hypotension on Induction"],"enrollment":291,"completionDate":"2016-12-01"},{"nctId":"NCT04354350","phase":"","title":"Replication of the ONTARGET Antihypertensive Trial in Healthcare Claims Data","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2017-09-22","conditions":["Hypertension"],"enrollment":63744,"completionDate":"2021-02-08"},{"nctId":"NCT05438316","phase":"PHASE1","title":"Bioequivalence Study of Two Formulations of Tablets Ramipril 10 mg in Healthy Volunteers Under Fasting Conditions","status":"COMPLETED","sponsor":"Pharmtechnology LLC","startDate":"2022-06-17","conditions":["Bioequivalence"],"enrollment":50,"completionDate":"2022-11-17"},{"nctId":"NCT02924727","phase":"PHASE3","title":"Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-12-09","conditions":["Acute Myocardial Infarction"],"enrollment":5669,"completionDate":"2021-02-26"},{"nctId":"NCT05271448","phase":"NA","title":"Continuing or Discontinuing ACE/ARBs in Patients With Chronic Kidney Disease Undergoing Coronary Angiography","status":"UNKNOWN","sponsor":"An-Najah National University","startDate":"2021-06-01","conditions":["Contrast-induced Nephropathy","Chronic Kidney Diseases","Ischemic Heart Disease"],"enrollment":600,"completionDate":"2024-08-01"},{"nctId":"NCT02817360","phase":"PHASE4","title":"NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients","status":"RECRUITING","sponsor":"Martin Huelsmann","startDate":"2016-02","conditions":["Heart Diseases","Diabetes Mellitus, Type 2"],"enrollment":2400,"completionDate":"2026-12"},{"nctId":"NCT03715998","phase":"PHASE2","title":"Firibastat or Ramipril After Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction","status":"COMPLETED","sponsor":"Quantum Genomics SA","startDate":"2019-06-04","conditions":["Myocardial Infarction"],"enrollment":295,"completionDate":"2021-07-08"},{"nctId":"NCT04962841","phase":"","title":"Nutraceuticals and Drug Treatment in Frail Older Adults","status":"UNKNOWN","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2020-04-01","conditions":["Frailty"],"enrollment":485,"completionDate":"2023-04-01"},{"nctId":"NCT03099213","phase":"PHASE4","title":"An Open-label, Non-comparative Study to Document the Tolerability to Ramipril in Patients With at Least One High Risk for Developing a Major Cardiovascular Event","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-11-01","conditions":["Coronary Artery Disease"],"enrollment":179,"completionDate":"2010-04-23"},{"nctId":"NCT03414723","phase":"PHASE1","title":"A Drug-Drug Interaction Study Between Sotagliflozin and Ramipril","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-01-15","conditions":["Diabetes Mellitus","Healthy Subjects"],"enrollment":16,"completionDate":"2018-03-10"},{"nctId":"NCT03011775","phase":"PHASE4","title":"Effect of Pioglitazone on Insulin Resistance, Atherosclerosis Progression and Clinical Course of Coronary Heart Disease","status":"COMPLETED","sponsor":"Ukrainian Medical Stomatological Academy","startDate":"2012-11","conditions":["Adverse Effect","Atherosclerosis, Coronary","Insulin Resistance Syndrome"],"enrollment":43,"completionDate":"2015-09"},{"nctId":"NCT02130687","phase":"NA","title":"Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2014-06","conditions":["Type 2 Diabetes Mellitus","Hypertension"],"enrollment":106,"completionDate":"2020-08"},{"nctId":"NCT02721342","phase":"","title":"Remission Clinic in Proteinuric Chronic Nephropathies","status":"UNKNOWN","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2009-06","conditions":["Chronic Kidney Disease"],"enrollment":1500,"completionDate":"2022-11"},{"nctId":"NCT02236806","phase":"PHASE3","title":"Cardiotoxicity Prevention in Breast Cancer Patients Treated With Anthracyclines and/or Trastuzumab","status":"UNKNOWN","sponsor":"Azienda Ospedaliero-Universitaria Careggi","startDate":"2015-07","conditions":["Breast Cancer","Cardiotoxicity"],"enrollment":262,"completionDate":"2022-06"},{"nctId":"NCT05133050","phase":"NA","title":"Safety and Efficacy of ACEI in Alport Syndrome Patients With COL4A3/COL4A4/COL4A5 Variants","status":"NOT_YET_RECRUITING","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2022-01-01","conditions":["Alport Syndrome"],"enrollment":510,"completionDate":"2026-12-31"},{"nctId":"NCT02499822","phase":"PHASE4","title":"REducing Blood Pressure Variability in Essential Hypertension With RAmipril vErsus Nifedipine GITS Trial","status":"COMPLETED","sponsor":"Istituto Auxologico Italiano","startDate":"2015-10","conditions":["Hypertension","High Blood Pressure Variability"],"enrollment":168,"completionDate":"2020-11-01"},{"nctId":"NCT03201185","phase":"PHASE4","title":"Renin-angiotensin System Blockade Benefits in Clinical Evolution and Ventricular Remodeling After Transcatheter Aortic Valve Implantation (RASTAVI)","status":"UNKNOWN","sponsor":"Hospital Clínico Universitario de Valladolid","startDate":"2018-02-10","conditions":["Transcatheter Aortic Valve Replacemen","Angiotensin-Converting Enzyme Inhibitors"],"enrollment":194,"completionDate":"2023-08"},{"nctId":"NCT01646437","phase":"PHASE3","title":"The International Polycap Study 3 (TIPS-3)","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2012-06","conditions":["Cardiovascular Disease","Fractures","Cancers"],"enrollment":7793,"completionDate":"2021-08-30"},{"nctId":"NCT04320589","phase":"PHASE2","title":"the Effect of Dexmedetomidine and Magnesium Sulfate in Open Resection of Pheochromocytoma","status":"COMPLETED","sponsor":"National Cancer Institute, Egypt","startDate":"2019-06-30","conditions":["Pheochromocytoma"],"enrollment":30,"completionDate":"2021-08-30"},{"nctId":"NCT03991910","phase":"PHASE3","title":"The Effect of Ramipril in Suppressing ST2 Expression in Rheumatic Mitral Stenosis Patients","status":"UNKNOWN","sponsor":"Indonesia University","startDate":"2019-06-27","conditions":["Rheumatic Heart Disease","Mitral Stenosis","Rheumatic Mitral Stenosis","Fibrosis; Heart","ACE Inhibitor"],"enrollment":66,"completionDate":"2024-08-08"},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":["Hypertension","COVID"],"enrollment":22213,"completionDate":"2020-12-31"},{"nctId":"NCT00421863","phase":"PHASE4","title":"Italian Study on the Cardiovascular Effects of Systolic Blood Pressure Control - CARDIOSIS Study","status":"COMPLETED","sponsor":"Heart Care Foundation","startDate":"2005-02","conditions":["Hypertension"],"enrollment":1111,"completionDate":"2009-01"},{"nctId":"NCT02086019","phase":"NA","title":"Revascularisation or Medical Therapy in Elderly Patients With Acute Anginal Syndromes","status":"COMPLETED","sponsor":"Brighton and Sussex University Hospitals NHS Trust","startDate":"2014-05-01","conditions":["Acute Coronary Syndromes"],"enrollment":250,"completionDate":"2019-12-12"},{"nctId":"NCT00985322","phase":"PHASE3","title":"Angiotensin-converting-enzyme (ACE) Inhibitors in Hemodialysis","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2009-05","conditions":["Left Ventricular Hypertrophy","Hypertension"],"enrollment":269,"completionDate":"2016-04"},{"nctId":"NCT04582097","phase":"PHASE2,PHASE3","title":"Ramipril in Pediatric Patients on Hemodialysis","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2018-12-01","conditions":["Hemodialysis"],"enrollment":135,"completionDate":"2020-02-28"},{"nctId":"NCT00980785","phase":"PHASE4","title":"Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2009-04-09","conditions":["Alzheimer's Disease","Hypertension"],"enrollment":14,"completionDate":"2011-07-26"},{"nctId":"NCT00535925","phase":"PHASE4","title":"Nephropathy In Type 2 Diabetes and Cardio-renal Events","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2005-10","conditions":["Diabetic Nephropathy"],"enrollment":850,"completionDate":"2019-05"},{"nctId":"NCT02632747","phase":"PHASE2","title":"Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-05-10","conditions":["Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2","Obesity"],"enrollment":31,"completionDate":"2019-07-02"},{"nctId":"NCT04330300","phase":"PHASE4","title":"Coronavirus (COVID-19) ACEi/ARB Investigation","status":"SUSPENDED","sponsor":"National University of Ireland, Galway, Ireland","startDate":"2020-04-30","conditions":["Hypertension","COVID-19"],"enrollment":2414,"completionDate":"2021-12-01"},{"nctId":"NCT01485978","phase":"PHASE3","title":"Efficacy and Safety Study to Delay Renal Failure in Children With Alport Syndrome","status":"COMPLETED","sponsor":"Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH","startDate":"2012-03","conditions":["Renal Insufficiency, Chronic"],"enrollment":66,"completionDate":"2019-03"},{"nctId":"NCT04364139","phase":"PHASE3","title":"African American Study of Kidney Disease and Hypertension","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"1995-02-01","conditions":["Hypertensive Nephrosclerosis","Chronic Renal Insufficiency"],"enrollment":1094,"completionDate":"2007-06-30"},{"nctId":"NCT01686230","phase":"NA","title":"Acupuncture in Patients With Stable Angina Pectoris","status":"COMPLETED","sponsor":"Chengdu University of Traditional Chinese Medicine","startDate":"2012-07","conditions":["Angina, Stable"],"enrollment":404,"completionDate":"2017-07"},{"nctId":"NCT02029118","phase":"EARLY_PHASE1","title":"Acupoint Application in Patients With Stable Angina Pectoris (AASAP)","status":"COMPLETED","sponsor":"Chengdu University of Traditional Chinese Medicine","startDate":"2012-10","conditions":["Stable Angina Pectoris"],"enrollment":200,"completionDate":"2015-08"},{"nctId":"NCT04262765","phase":"PHASE1","title":"Drug-drug-interaction Study of Ramipril, Amlodipine and Atorvastatin","status":"COMPLETED","sponsor":"Midas Pharma GmbH","startDate":"2019-02-23","conditions":["Healthy Volunteers"],"enrollment":18,"completionDate":"2019-03-26"},{"nctId":"NCT04143412","phase":"PHASE2","title":"Efficacy of ACE Inhibitors, MRAs and ACE Inhibitor/ MRA Combination","status":"UNKNOWN","sponsor":"Beni-Suef University","startDate":"2019-02-04","conditions":["Diabetic Nephropathy Type 2","Microalbuminuria Due to Type 2 Diabetes Mellitus"],"enrollment":75,"completionDate":"2020-03"},{"nctId":"NCT00512759","phase":"PHASE4","title":"Goal-directed Afterload Reduction in Acute Congestive Cardiac Decompensation Study","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2007-12-10","conditions":["Acute Heart Failure"],"enrollment":781,"completionDate":"2019-02-21"},{"nctId":"NCT00574834","phase":"EARLY_PHASE1","title":"Mechanisms of Ramipril Reduction in the Onset of Type 2 Diabetes","status":"TERMINATED","sponsor":"University of Maryland, Baltimore","startDate":"2007-03","conditions":["Metabolic Syndrome"],"enrollment":17,"completionDate":"2014-08"},{"nctId":"NCT02200822","phase":"PHASE4","title":"Systematic Withdrawal of Neurohumoral Blocker Therapy in Optimally Responding CRT Patients","status":"COMPLETED","sponsor":"Hasselt University","startDate":"2014-07","conditions":["Heart Failure (HF)"],"enrollment":80,"completionDate":"2019-02"},{"nctId":"NCT03979976","phase":"PHASE2,PHASE3","title":"Ramipril, Endothelial Function and Endothelial Progenitor Cells in Patients With Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2011-03","conditions":["Systemic Lupus Erythematosus"],"enrollment":37,"completionDate":"2013-09"},{"nctId":"NCT02832973","phase":"PHASE4","title":"Sequential Nephron Blockade vs. Dual Blockade Renin-angiotensin System + Bisoprolol in Resistant Arterial Hypertension","status":"COMPLETED","sponsor":"Sao Jose do Rio Preto Medical School","startDate":"2015-09","conditions":["Hypertension Resistant to Conventional Therapy"],"enrollment":72,"completionDate":"2018-03"},{"nctId":"NCT03770936","phase":"PHASE3","title":"Effect of Some Drugs on Liver Fibrosis","status":"RECRUITING","sponsor":"Sherief Abd-Elsalam","startDate":"2018-10-01","conditions":["Liver Fibroses"],"enrollment":45,"completionDate":"2027-11"},{"nctId":"NCT01234922","phase":"PHASE2","title":"Benazepril Hydrochloride, Lisinopril, Ramipril, or Losartan Potassium in Treating Hypertension in Patients With Solid Tumors","status":"TERMINATED","sponsor":"Wake Forest University Health Sciences","startDate":"2011-02","conditions":["Hypertension","Unspecified Adult Solid Tumor, Protocol Specific"],"enrollment":6,"completionDate":"2014-04"},{"nctId":"NCT00741585","phase":"PHASE4","title":"Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment","status":"COMPLETED","sponsor":"University of Vigo","startDate":"2008-09-01","conditions":["Essential Hypertension","Cardiovascular Disease","Stroke","Chronic Kidney Disease"],"enrollment":21983,"completionDate":"2018-06-30"},{"nctId":"NCT00702091","phase":"NA","title":"Bioequivalency Study of Ramipril 10 mg Capsules Under Fasting Conditions","status":"COMPLETED","sponsor":"Roxane Laboratories","startDate":"2005-01","conditions":["Hypertension"],"enrollment":39,"completionDate":"2005-01"},{"nctId":"NCT00702260","phase":"NA","title":"Bioequivalency Study of Ramipril 10 mg Capsules Under Fed Conditions","status":"COMPLETED","sponsor":"Roxane Laboratories","startDate":"2005-01","conditions":["Hypertension"],"enrollment":39,"completionDate":"2005-01"},{"nctId":"NCT00281593","phase":"PHASE3","title":"Telmisartan (Micardis) and Ramipril (Altace) - Factorial Design Study for the Treatment of Hypertension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-04","conditions":["Hypertension"],"enrollment":1354,"completionDate":""},{"nctId":"NCT01867047","phase":"NA","title":"ACE-Inhibitor Effects on Total Hip and Knee Arthroplasty Patients","status":"TERMINATED","sponsor":"Duke University","startDate":"2013-06","conditions":["Adverse Effects of Angiotensin-converting-enzyme Inhibitors","Hypotension"],"enrollment":59,"completionDate":"2016-06-24"},{"nctId":"NCT01715584","phase":"PHASE4","title":"Is There an Adverse Drug Reaction Between Renin-Angiotensin System Blockade and Inhaled Anesthetics","status":"UNKNOWN","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2012-07","conditions":["Hypertension"],"enrollment":80,"completionDate":"2019-12-31"},{"nctId":"NCT00608465","phase":"PHASE4","title":"Defining Strategies for Improving Endothelial and Fibrinolytic Dysfunction in Obesity","status":"TERMINATED","sponsor":"Vanderbilt University","startDate":"2006-05","conditions":["Metabolic Syndrome X"],"enrollment":4,"completionDate":"2011-05"},{"nctId":"NCT01856361","phase":"NA","title":"Ramipril for the Treatment of Oligospermia","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2013-07","conditions":["Oligospermia","Teratospermia","Asthenozoospermia","Male Infertility"],"enrollment":2,"completionDate":"2016-06"},{"nctId":"NCT00367939","phase":"PHASE3","title":"Efficacy and Safety of the Combination of Valsartan Plus Amlodipine in Hypertensive Patients Not Adequately Responding to the Combination Therapy With Ramipril Plus Felodipine","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-12","conditions":["Hypertension"],"enrollment":132,"completionDate":"2006-07"},{"nctId":"NCT00219089","phase":"PHASE3","title":"A Clinical Study to Evaluate the Safety and Efficacy of Aliskiren Alone and in Combination With Ramipril in Hypertensive, Diabetic Patients.","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-11","conditions":["Hypertension, Diabetes Mellitus"],"enrollment":839,"completionDate":"2005-08"},{"nctId":"NCT00219063","phase":"PHASE3","title":"A Clinical Study to Compare an Aliskiren Based Hypertensive Regimen With a Ramipril Based One Followed by a Randomized Withdrawal.","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-02","conditions":["Hypertension"],"enrollment":844,"completionDate":"2006-03"},{"nctId":"NCT02791958","phase":"PHASE2","title":"Pharmacodynamic Equivalence of Ramipril 10 mg and Atorvastatin 40 mg Administered as a Cardiovascular (CV) Polypill Acetylsalicylic Acid-Atorvastatin-Ramipril (AAR) as Compared to Monotherapy","status":"UNKNOWN","sponsor":"Ferrer Internacional S.A.","startDate":"2016-03","conditions":["Hypertension"],"enrollment":528,"completionDate":"2017-10"},{"nctId":"NCT01504828","phase":"NA","title":"Cardiac Energetics and Function in Normal Human Ageing","status":"COMPLETED","sponsor":"Newcastle-upon-Tyne Hospitals NHS Trust","startDate":"2012-07","conditions":["Left Ventricular Function Systolic Dysfunction","Left Ventricular Function Diastolic Dysfunction","Ageing"],"enrollment":135,"completionDate":"2015-12"},{"nctId":"NCT00946621","phase":"PHASE1","title":"To Demonstrate the Relative Bioavailability Study of Ramipril 10 mg Capsules Under Non-Fasting Conditions","status":"COMPLETED","sponsor":"Sandoz","startDate":"2004-10","conditions":["Hypertension"],"enrollment":48,"completionDate":"2004-11"},{"nctId":"NCT00946465","phase":"PHASE1","title":"To Demonstrate the Relative Bioavailability Study of Ramipril 10 mg Capsules Under Fasting Conditions","status":"COMPLETED","sponsor":"Sandoz","startDate":"2004-10","conditions":["Hypertension"],"enrollment":48,"completionDate":"2004-11"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Capsule, Tablet","formulations":[{"form":"CAPSULE","route":"ORAL","productName":"RAMIPRIL"},{"form":"CAPSULE","route":"ORAL","productName":"Ramipril"},{"form":"CAPSULE","route":"ORAL","productName":"ALTACE"},{"form":"CAPSULE","route":"oral","productName":"Ramipril"},{"form":"CAPSULE, GELATIN COATED","route":"ORAL","productName":"RAMIPRIL"},{"form":"TABLET","route":"ORAL","productName":"RAMIPRIL"},{"form":"TABLET","route":"ORAL","productName":"Ramipril"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000147662","MMSL":"130231","NDDF":"003585","UNII":"L35JN3I7SJ","VUID":"4019562","CHEBI":"CHEBI:8774","VANDF":"4019562","INN_ID":"5561","RXNORM":"1546377","UMLSCUI":"C0072973","chemblId":"CHEMBL1168","ChEMBL_ID":"CHEMBL1168","KEGG_DRUG":"D00421","DRUGBANK_ID":"DB00178","PDB_CHEM_ID":" X92","PUBCHEM_CID":"5362129","SNOMEDCT_US":"108564000","IUPHAR_LIGAND_ID":"6339","SECONDARY_CAS_RN":"87269-97-4","MESH_DESCRIPTOR_UI":"D017257","MESH_SUPPLEMENTAL_RECORD_UI":"C052549"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1991-","companyName":"King Pharms","relationship":"Original Developer"},{"period":"present","companyName":"King Pfizer","relationship":"Current Owner"}],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"28%"},"publicationCount":2601,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"C09AA05","allCodes":["C09AA05","C09BA05","C09BB05","C09BB07","C09BX03","C09BX05","C10BX04","C10BX06","C10BX17","C10BX18"]},"biosimilarFilings":[],"originalDeveloper":"King Pharms","recentPublications":[{"date":"2026 Mar 20","pmid":"41898697","title":"Steroid-Resistant Focal Segmental Glomerulosclerosis with Alport-like Glomerular Basement Membrane Lesions Due to a MYO1E Mutation: A Pediatric Case Report.","journal":"International journal of molecular sciences"},{"date":"2026 Mar 17","pmid":"41844720","title":"Sexual function among controlled and uncontrolled hypertensive females receiving beta-blockers or ACEI/ARB and thiazides: a prospective randomized controlled study.","journal":"Scientific reports"},{"date":"2026 Mar 11","pmid":"41810798","title":"Systemic medications associate with surgically treated cataract among adults over 50 years in Finland.","journal":"Acta ophthalmologica"},{"date":"2026 Mar 4","pmid":"41779342","title":"Challenges and Perspectives in Optimising the Treatment of Arterial Hypertension: Role of the Ramipril-Amlodipine-Hydrochlorothiazide Single-Pill Combination.","journal":"High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension"},{"date":"2026 Mar 3","pmid":"41774060","title":"Cardioprotective effects of prophylactic ACE inhibitors in anthracycline-induced cardiotoxicity: a systematic review and meta-analysis of randomized trials.","journal":"Journal of cardiovascular pharmacology"}],"companionDiagnostics":[],"genericManufacturers":17,"_genericFilersChecked":true,"genericManufacturerList":["Accord Hlthcare","Actavis Elizabeth","Apotex","Aurobindo Pharma Ltd","Chartwell Molecular","Chartwell Rx","Cipla","Corepharma","Hikma","Lupin","Natco Pharma","Ranbaxy Labs Ltd","Senores Pharms","Teva Pharms","Watson Labs","Zydus Pharms Usa","Zydus Pharms Usa Inc"],"status":"approved","companyName":"King Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"1991","aiSummary":"","enrichmentLevel":4,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1991-01-28T00:00:00.000Z","mah":"KING PHARMS","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"patentsNormalised":[{"patent_number":"12343338","territory":"US","patent_type":"Formulation","expiry_date":"2039-08-16T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"trialStats":{"total":2,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T05:56:56.397417+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}